High-relaxivity systems and molecular imaging probes for Magnetic Resonance Imaging applications by G. Gambino
1 
 
 
 
 
 
 
Università degli studi del Piemonte Orientale 
“Amedeo Avogadro” 
Dipartimento di Scienze e Innovazione Tecnologica 
 
High-relaxivity systems and molecular imaging 
probes for Magnetic Resonance Imaging 
applications 
 
 Giuseppe Gambino 
 
PhD supervisor: Prof. Mauro Botta 
PhD Co-supervisor: Dr. Lorenzo Tei 
A thesis submitted for PhD degree 
January 2014 
2 
 
Contents 
Chapter 1: Introduction ................................................................................ 5 
1.1  Magnetic Resonance Imaging ........................................................................ 5 
1.2 Relaxivity, contributions and parameters ..................................................... 8 
1.3  Gd3+ complexes, an introduction to MRI contrast agents ........................ 10 
1.4 Enhancing MRI CAs efficiency ..................................................................... 12 
1.4.1 Supramolecular systems ................................................................. 17 
1.4.2 Nanosized lipidic systems .............................................................. 24 
1.4.2.1 Self-assembling aggregates of amphiphilic Gd(III) 
complexes ....................................................................................... 25 
1.4.2.2 Lipid nanoparticles: micelles ........................................... 32 
1.4.2.3 Lipid nanoparticles: Liposomes ...................................... 39 
1.4.3 Blood pool agents ............................................................................. 47 
1.4.4. Organ-specific agents ..................................................................... 51 
1.4.5  Targeting and cell labelling ........................................................... 54 
1.5 Aim of the work .............................................................................................. 58 
References .............................................................................................................. 60 
 
Chapter 2: AAZTA-Dimer, a novel building block for high relaxivity 
systems ........................................................................................................... 73 
2.1   Synthetic procedure ...................................................................................... 74 
2.2  Thermodynamic study .................................................................................. 76 
2.3  Kinetic study ................................................................................................... 80 
2.4  1H relaxometric properties ..........................................................................  83 
2.5  Conclusions ..................................................................................................... 85 
2.6 Experimental part ........................................................................................... 86 
References .............................................................................................................. 88 
 
Chapter 3: AAZTA-dimer functionalization with an adamantyl moiety 
and  formation of supramolecular inclusion compounds ................... 89 
3.1 Synthetic Procedure ........................................................................................ 91 
3 
 
3.2 1H relaxometric study .................................................................................... 92 
3.2.1 Supramolecular adducts with β-CD and poly-β-CD .................. 96 
3.2.1 Interaction with HSA ....................................................................... 99 
3.3 In vivo MRI analysis ..................................................................................... 101 
3.4 Conclusions .................................................................................................... 104 
3.5 Experimental part ......................................................................................... 105 
References ............................................................................................................ 108 
 
Chapter 4: AAZTA-dimer functionalization as a multimodal optical-
MRI imaging reporter ............................................................................... 111 
4.1 Synthetic Procedure ...................................................................................... 113 
4.2 Relaxometric measurements ....................................................................... 115 
4.3 Cell study ....................................................................................................... 117 
4.4 Conclusions .................................................................................................... 120 
References ............................................................................................................ 121 
 
 
Chapter 5: Lipid nanoparticles including multimeric Gd3+ complexes
 ....................................................................................................................... 123 
5.1 Synthetic Procedure ...................................................................................... 124 
5.2 Relaxometric and DLS study ....................................................................... 126 
5.2.1 Self-aggregated systems ................................................................ 126 
5.2.2 Interaction with HSA ..................................................................... 131 
5.2.3 Mixed micelles and inclusion into liposome bi-layer ............... 134 
5.3 Conclusions .................................................................................................... 141 
5.4 Experimental part ......................................................................................... 142 
References ............................................................................................................ 145 
 
 
4 
 
  
5 
 
 
1. Introduction 
1.1  Magnetic Resonance Imaging  
Magnetic resonance imaging (MRI) is a powerful and widely used diagnostic tool in 
modern clinical medicine because of its many advantages as a diagnostic imaging 
modality. It is noninvasive, delivers non-ionizing radiation, and has excellent 
(submillimeter) spatial resolution. The soft tissue contrast is good enough to allow MRI 
to give detailed anatomical information. Moreover, there are many techniques that can 
provide contrast in MRI, resulting in markedly different images from the same 
anatomical region. For instance, pulse sequences can be weighted to highlight 
differences among tissues that have different proton density , T1 or T2 relaxation times 
(Figure 1.1), different rates of water diffusion, or different chemical shifts (water vs 
lipids). The overriding challenge with MRI is its relatively low sensitivity. Hydrogen 
atoms from water, present in tissue at ~90 M concentration, are the main observation 
in clinical imaging. In order to induce additional contrast, a substance is required that 
will affect some of the properties of the 90 M water protons as much as an observable 
effect is achieved. Such substances are called MRI contrast agents. They are 
paramagnetic, superparamagnetic, or ferromagnetic compounds that catalytically 
shorten the relaxation times of bulk water protons. 
 
   
Figure 1.1 T1 weighted (left), T2 weighted (centre) and ρ weighted (right) brain 
images. 
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All contrast agents shorten both T1 and T2. However it is useful to classify MRI contrast 
agents into two broad groups based on whether the substance increases the transverse 
relaxation rate (1/T2) by roughly the same amount that it increases the longitudinal 
relaxation rate (1/T1) or whether 1/T2 is altered to a much greater extent. The first 
category includesas the so-called T1 agents because, on a percentage basis, these agents 
alter 1/T1 of tissue more than 1/T2 owing to the fast endogenous transverse relaxation 
in tissue. With most pulse sequences, this dominant T1 lowering effect gives rise to 
increases in signal intensity; these are positive contrast agents. The T2 agents largely 
increase the 1/T2 of tissue and cause a reduction in signal intensity; these are negative 
contrast agents. Paramagnetic gadolinium3+ based contrast agents are examples of T1 
agents, while ferromagnetic iron oxide particles are examples of T2 agents. Although 
there are some manganese2+ and iron-based contrast agents approved for clinical use, 
the overwhelming majority of contrast enhanced clinical exams are performed with 
Gd3+ complexes.  
 
Figure 1.2: MRI images of breast cancer pre (left) and after (right) contrast agent 
administration. [From University of Liverpool website; 
http://int.ch.liv.ac.uk/Lanthanide/Ln_Chemistry_folder/MRI%20folder/MRImages.
html] 
 
More than 10 million MRI studies are performed using Gd3+-based contrast agents 
each year. It is the action of the contrast agent on the relaxation properties of the water 
hydrogen nuclei that enhance contrast; this is different from X-ray contrast media and 
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nuclear imaging agents where the observed effect is more proportional to the 
concentration of iodine or radionuclide. Since water is present at a much higher 
concentration than the contrast agent, the latter must act catalytically to relax the water 
protons in order to observe an effect. The ability of a contrast agent to change a 
relaxation rate is represented quantitatively as relaxivity, r1 or r2, where the subscript 
refers to either the longitudinal (1/T1) or the transverse relaxation rate (1/T2). 
Relaxivity is simply the change in relaxation rate after the introduction of the contrast 
agent ((1/T1) normalized to the concentration of contrast agent or metal ion [M] 
(equation 1). 
𝑟1 =
∆(
1
𝑇1
)
[𝑀]
                                                               (1) 
To enhance the role of MR in molecular and cellular imaging investigations, it is 
necessary to improve the sensitivity of the involved probes. The sensitivity issue deals 
with either the intrinsic relaxivity of a given agent or specific features associated with 
the biological characteristics of the targeting experiments. As far as the intrinsic 
sensitivity is concerned, the chemist has to design systems endowed with structural 
and dynamic properties that lead to optimized values for those parameters that are 
relevant for a given contrast enhancing mechanism. Much work has been done in the 
last two decades to design structures with high relaxivity; however the theoretical 
maximum efficiency expected from the optimization of all the parameters involved in 
the paramagnetic relaxation has not yet been reached. In general, to attain the MR 
visualization of a given cellular target, one may rely on the exploitation of high-
capacity carriers that can be loaded with a huge number of imaging reporters, thus 
allowing the internalization of a sufficient amount of contrast agent in the target cells. 
This approach has required the use of macromolecular and supramolecular systems 
that chemists had primarily developed for the setup of drug delivery experiments. 
Depending on their characteristics, the carriers may be loaded with commercial Gd 
agents or specifically tailored probes may need to be prepared in order to be 
compatible with the structure of the carrier. Interestingly, other than the molecular 
parameters, it has been envisaged that, for some types of nanocarriers, other 
contributions may be important for the creation of longitudinal relaxivity values that 
8 
 
would be much higher than the ones that are currently available. These contributions 
will be discussed in the following chapter. 
 
 
1.2  Relaxivity, contributions and parameters  
The relaxivity enhancement of water protons in aqueous solutions of Gd3+ complexes 
arises from time fluctuation of the dipolar coupling between the electron magnetic 
moment of the metal ion and the nuclear magnetic moment of the solvent nuclei.  
 
Figure 1.3: Illustration of the three types of hydration layers around a Gd3+ 
complex and the most relevant parameters of paramagnetic relaxation[botta rev2000]. 
 
This interaction is traditionally described with a model that considers two 
contributions (Figure 1.3): inner sphere (IS), due to water molecules present in number 
q in the coordination sites of the Gd3+ ion, and outer sphere (OS), which involves all 
the solvent molecules diffusing by the complex: 
𝑅1
𝑜𝑏𝑠 =  𝑅1𝑝
𝐼𝑆  + 𝑅1𝑝
𝑂𝑆 +  𝑅1
𝑊                                                                                               (2)               
 where R1obs is the measured relaxation rate and R1W the relaxation rate of the solvent 
in the absence of the paramagnetic complex.  
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The inner sphere contribution is the term that most contributes to r1p. This is the reason 
why large efforts towards contrast agents of improved efficacy have been directed 
mainly towards its optimization. The large number of experimental data recorded over 
the last 15 years on small Gd3+ chelates have been interpreted on the basis of the 
Solomom-Bloembergen-Morgan approach, and have provided a good understanding 
of the role played by the different relaxation parameters, of their mutual relationship, 
and of their dependence on the structural features of the complexes. The relevant 
Equations are: 
 
𝑅1𝑝
𝐼𝑆 =
[𝑀]𝑞
55.6
 
1
𝑇1𝑀 + 𝜏𝑀
                                                                                               (3) 
 
1
𝑇1𝑀
=  
2
15
 
𝛾𝐻
2𝑔2𝑆(𝑆 + 1)𝛽2
𝑟𝐻
6  [
3𝜏𝐶1
1 + 𝜔𝐻
2 𝜏𝐶1
2 +
7𝜏𝐶2
1 + 𝜔𝑆
2𝜏𝐶2
2 ]                                   (4) 
 
1
𝜏𝐶𝑖
=
1
𝜏𝑅
+
1
𝜏𝑀
+
1
𝜏𝑆𝑖
                                                                                                    (5) 
 
where M is the concentration of the CA, T1M the longitudinal relaxation time of  the 
bound water protons, S is the electron spin quantum number (7/2 for Gd3+), H is the 
proton nuclear gyromagnetic ratio,  is the Bohr magneton, g is the Landè factor for 
the free electron, rH is the distance between the metal ion and the bound water protons; 
H and S are the proton and electron Larmor frequencies, respectively, and τCi (i= 1, 
2) are the correlation times of the modulation of the dipolar electron-proton coupling. 
The overall correlation times τCi receive contributions from the reorientation of the 
paramagnetic species, τR, by the residence lifetime of the bound water protons, τM and 
by the electronic relaxation times of the metal ion, τS. A marked enhancement of r1p at 
the magnetic fields currently employed clinically has been primarily obtained by 
slowing down the molecular tumbling (increasing τR) by different approaches. 
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However, the expected increase of r1p has not been observed because of the limiting 
effect of the mean water residence lifetime τM.[1-5] 
A fine tuning of this parameter has emerged as a primary objective of the current 
research in this field, as only values around 30 ns would allow the full exploitation of 
the decrease of T1M induced by the lengthening of τR. 
 
 
1.3  Gd3+ complexes, an introduction to MRI contrast agents 
 
The sensitivity of a given paramagnetic complex is closely related to its relaxivity  
(usually measured at 0.5 T and at 298 or 310 K). Relaxivity is the result of a complex 
interplay between the paramagnetic center’s structural, dynamic, and electronic 
properties. Good estimates of the determinants of the relaxivity of a given 
paramagnetic complex can be obtained from the analysis of relaxivity data as a 
function of the applied magnetic field (NMRD profiles). This method gave rise to a 
prediction that high relaxivities could be attained, at the clinical field strength of 0.5-
1.5 T, by lengthening the molecular reorientational time, τR.  
Therefore, macromolecular systems were addressed by either the covalent or 
noncovalent binding of paramagnetic chelates to slowly moving substrates. Human 
serum albumin (HSA), the most abundant protein in serum, has often been an 
important target for the development of a high-sensitivity agent for magnetic 
resonance angiography.[6] 
The relaxivities observed for HSA adducts were often lower than expected as a 
consequence of the increase in the residence lifetime (τM) of the water molecule at 
the metal site.[7]   Moreover, it has been recently shown that, in addition to steric 
hindrance at the coordination metal site, τM  is strongly modulated by the charge at the 
metal ion, thus reflecting changes that occur at the level of the donor atoms of the 
coordination cage.[8] 
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Thus, the formation of hydrogen bonds between the carboxylic groups of the ligand 
and basic amino acids on the surface of the protein may result in a significant release 
of the residual electric charge on the complex that, in turn, yields a marked elongation 
of the exchange lifetime of the coordinated water molecule(s). Of course, the 
coordinated water itself may be involved in H-bond formation that directly affects its 
dissociation kinetics. Thus, upon binding to a protein (or more generally to a 
macromolecular substrate), the relaxivity of a given paramagnetic complex may vary 
as a consequence not only of τR but also of τM. Both parameters are site-dependent. In 
fact, the complex very seldom assumes the molecular reorientational time of the 
macromolecule, but rather it experiences a faster reorientation motion superimposed 
onto the slower motion of the supramolecular adduct. Clearly, the “pincer attack” of 
the complex at two binding sites endows the system with the τR of the macromolecule 
as shown by Caravan and co-workers.[9] 
Figure 1.4: Average size of the nanocarriers considered so far for developing highly 
sensitive Gd(III)-based MRI agents. [Aime et al. Vol. 42, No. 7 July 2009 822-831 
ACCOUNTS OF CHEMICAL RESEARCH 823]  
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Another issue related to the overall sensitivity of Gd3+-based probes is the “clustering” 
effect. Some years ago, Merbach and co-workers showed that the dilution of Gd3+ 
chelates with diamagnetic Y3+ complexes at the surface of micelles resulted in an 
enhanced relaxivity. [10] 
The observed behavior was ascribed to the occurrence of dipolar interactions among 
the Gd3+ ions able to enhance the electronic relaxation rate that, in turn, causes the 
decrease of the observed relaxation rate in neat Gd3+-containing micelles. 
The link between relaxivity and local concentration has also been recently tackled by 
Sherry and co-workers, who used a Gd-DO3A-peptide chimera able to bind anti-FLAG 
monoclonal antibodies. [11] The relaxivity of the supramolecular Gd-DO3A-antibody 
adduct was only ∼17 mM-1 s-1 (likely due to a long τM), and the system was MR silent 
at concentrations below ∼9 µM. However, when the antibodies were clustered 
together to form microdomains of high local concentration at the surface of agarose 
beads, the MR detection limit of the agent improved down to 4 µM. On the basis of 
simulated data, the authors concluded that the detection limit of a single highly 
efficient low molecular weight Gd3+ agent (relaxivity of 100 mM-1 s-1) targeted in a 
protein microdomain is ∼0.7 µM at 9.4 T, thus suggesting that small sized agents could 
still have a future in MR molecular imaging applications.  
 
 
1.4 Enhancing MRI CAs efficiency 
Extracellular MRI contrast agents like Magnevist® ([Gd(DTPA)(H2O)]2- (Figure 1.5) 
are cheap to produce and have an excellent safety profile. Doses as high as 0.3 mmol 
kg-1 are given clinically for angiography and cerebral perfusion applications. At these 
doses, T1 in the presence of contrast agent is much shorter than T1 in any other tissue 
and therefore contrast is excellent. The drive for higher relaxivity doesn’t come from 
making a better Magnevist, whereas from increasing the sensitivity of MRI to detect 
molecular targets. 
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In order to induce observable contrast in a robust clinical exam, a relaxation rate  
change of at least 0.5 s-1 is required. For extracellular commercial contrast agents with 
a relaxivity of ~4 mM-1 s-1 , this means a concentration of ~125 mM. For targeted 
imaging and assuming a 1 : 1 binding stoichiometry (Gd : target molecule), this would 
require a biological target present with a concentration at least 125 mM. 
 
 
Figure 1.5: Some commercial MRI CAs. 
For absolute sensitivity, a more rigorous analysis by Wedeking et al.  gave a limit  of 
detection of 30 mM in mouse skeletal muscle for the contrast agent 
Gd(HPDO3A)(H2O)]. This limits the number of potential biological targets for 
imaging using current technology.  In order to achieve sufficient T1 change, relaxivity 
and/or the number of Gd/molecule should be increased. Being relaxivity so 
dependent on molecular motion, molecular size, rigidity, and a possible protein 
binding, it must be optimized on a case by case basis. There is no ‘‘high relaxivity’’ 
gadolinium complex that can be conjugated to a targeting vector that will necessarily 
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give a targeted contrast agent with high relaxivity. The rotational dynamics of the final 
molecule are critical and there are a lot of ways to obtain a MRI contrast agent suitable 
for molecular targeting taking advantage of this parameter.  
Water proton relaxation by Gd3+ occurs via a dipolar mechanism and as such has a 
1/r6 dependence on the distance between the ion and the nucleus, as described in 
equation (4). Because of this, it is critical to have one or more exchangeable waters in 
the inner coordination sphere. However if the hydration number, q, is greater than one 
then the complex should be stable with respect to water displacement by endogenous 
ligands.  
Ultimately for in vivo use, the complex must be stable and kinetically inert with respect 
to gadolinium loss. Water exchange in and out of the first coordination sphere should 
be fast. In order to increase the relaxation rate of bulk solvent two things must occur: 
the paramagnetic ion should efficiently relax the water that comes into contact with it, 
and the relaxed water should exchange rapidly with the bulk water. 
For fast tumbling complexes such as [Gd(DTPA)(H2O)]2-, it is relaxation of the bound 
water that is the rate limiting process. Water exchange becomes important when 
rotational motion is slowed. Gadolinium complexes with amide oxygen donor atoms 
have typically slower water exchange rates. [12] 
The gadolinium complex of the bis(N-methyl)amide analog of DTPA, [Gd(DTPA- 
BMA)(H2O)], has a water exchange rate about 10 times slower than that of 
[Gd(DTPA)(H2O)]-2. In the presence of serum albumin, both complexes bind with it, 
resulting in much slower tumbling and a more efficient relaxation mechanism of the 
bound water. Now the relative importance of water exchange becomes significant and 
the slow water exchange at the GdDTPA-BMA derivative limits its relaxivity. 
Increasing water exchange may improve relaxivity further, but only if the process for 
relaxing the bound water is very efficient. 
For most biological targets of interest for imaging, multiple gadolinium ions are 
required to provide the necessary relaxation rate change. Linking multiple complexes 
together necessarily increases the effective correlation time for motion. 
15 
 
However, understanding and controlling rotational flexibility has a large impact on 
the resultant relaxivity. Linking complexes in a linear fashion gives an oligomer with 
anisotropic rotation where rotation about the short axis of the molecule is fast and 
limits relaxivity. Dendrimers linked to gadolinium complexes usually have higher 
relaxivity because the dendritic structure imposes a more isotropic rotational dynamic 
optimizing the effect of the increased molecular weight on relaxivity. The different 
types of motion are illustrated in Figure 1.6.  
 
Figure 1.6: Different constructs for increasing relaxivity. a) Linear polymer increases 
the number of Gd per molecule but low relaxivity because of flexibility/internal 
motion. b) Dendrimer increases the number of Gd per molecule and introduces 
more globular structure, slowing rotation and increasing relaxivity; internal motion 
still present. c) Monomer with Gd at barycenter of molecule; although the non-Gd 
containing arms are free to rotate, the Gd can only rotate at the rate of the entire 
molecule resulting in high relaxivity. [Caravan, Chem. Soc. Rev., 2006, 35, 512–523] 
 
An example of a linear polymer is that described by Casali et al.[13] who reported a 
modified dextran polymer with DOTA-monoamide chelates with a total molecular 
weight of 52 kDa. The per-gadolinium relaxivity of this multimeric compound was 
10.6 mM-1 s-1 (37 °C, 0.47 tesla). The same type of gadolinium chelate appended 24 
times to a polyamide dendrimer gives the compound Gadomer (also called Gadomer-
17 because of its 17 kDa molecular weight). Under similar conditions (40 °C, 0.47 tesla), 
Gadomer has a relaxivity of 16.5 mM-1 s-1 per gadolinium.[14] 
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Figure 1.7: Rigid self-assembly to increase relaxivity. Bottom: 3 Gd complexes 
with pendant bidentate ligands assemble around transition metal ion to increase 
molecular weight and increase relaxivity. Top: Example from Livramento et al.[18] 
where three bipy ligands with two q = 2 Gd complexes coordinate Fe(II) to yield 
a compact assembly with high relaxivity. 
 
The gadolinium chelates in the dendrimer can also undergo internal motion about 
the linkages to the dendrimer core. Another approach to optimizing the effect of 
motion on relaxivity is to place the gadolinium at the barycenter of the molecule. 
The Guerbet group synthesised and studied a Gd-agent called gadomelitol (also 
called P792 or Vistarem) that can be described as a GdDOTA complex with large 
hydrophilic groups appended to each of the -carbons on the acetate arms.[15] 
Although there is flexibility within the hydrophilic arms, the Gd-Hwater vector 
cannot rotate independently of the entire molecule. This lack of internal motion 
results in a remarkably high relaxivity, r1 = 39.0 mM-1 s-1  (37 °C, 0.47 tesla) for a 
molecule of its size, 6.4 kDa. Parker and coworkers[16] have showed that this 
rotational effect can be modulated by adjusting the size of the hydrophilic ‘‘arms’’.  
Another approach for controlling rotational flexibility is the metal templated self-
assembly approach described by Jacques and Desreux.[17] They proposed to to 
append gadolinium complexes to rigid bidentate or tridentate ligands, and then 
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using a transition metal to assemble the gadolinium complexes in a rigid, compact 
space, (Figure 1.7 bottom). Livramento et al.[18] extended this by using q = 2 
gadolinium complexes. Two complexes are covalently linked to a bipyridyl ligand. 
Three of these bipyridyl ligands coordinate Fe2+ in an octahedral fashion resulting 
in a high relaxivity per Gd3+ and per molecule, especially impressive given its high 
Gd3+ content and relatively low molecular weight. The per Gd3+ relaxivity of the 
starting material bipyridyl Gd3+ dimer (Figure 1.7, top left) is 12.5 mM-1 s-1 (40 MHz, 
37 °C), which is extremely good compared to the r1 value of 3.8 mM-1 s-1 for 
[Gd(DTPA)(H2O)] measured under the same conditions. The increased relaxivity 
stems from having two exchangeable waters and an increased molecular weight. 
In the presence of Fe2+, the bipy ligands coordinate and the Gd3+ ions are now part 
of a rigid molecule with a much longer correlation time and the relaxivity doubles 
to 26.5 mM-1 s-1 . This is a very efficient relaxation agent from a synthetic 
perspective as well; it is a high relaxivity complex that is about 25% Gd3+ by weight. 
 
 
1.4.1 Supramolecular systems  
The obvious way to enhance relaxivity is to increase the system R. It is likely that 
rigidity will play a role in optimizing R as a function of molecular weight. The 
limitations of slow water exchange on relaxation rate have been recognized, and 
there is a growing body of evidence to aid in optimizing M. Increasing the 
hydration number poses some interesting challenges to maintain thermodynamic 
stability/kinetic inertness and, at the same time, to be resistant to formation of 
ternary complexes with endogenous ligands such as phosphate and carbonate. 
However, increasing q offers a large reward in terms of obtainable relaxivities. 
Another interesting field in the way to increase MRI contrast agents relaxivity is 
the choose of ligand coordinating donor atoms, because they are intrinsically 
responsible of the second sphere of coordination of water molecules. Outer-sphere 
relaxation is still quite a misunderstood entity receiving little attention. This bias is 
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understandable considering the composition of the clinically available complexes 
coupled with the need for thermodynamically stable complexes.  
The conjugation of low molecular weight chelates such as GdDTPA or GdDOTA 
to macromolecules alters the biophysical and pharmacological properties of low 
molecular weight agents.[19] From the biophysical point of view, the conjugation of 
Gd3+ chelates to polymeric materials was anticipated to increase the rotational 
correlation time and, hence, to improve the relaxivity per Gd3+ atom. Combined 
with tissue-specific targeting moieties, macromolecular conjugates were also 
envisioned to provide MRI with the ability to image low-concentration receptors 
by delivering a large payload of Gd3+ chelates. High molecular weight conjugates 
are retained in the vascular space because of their molecular size and thus facilitate 
blood pool imaging. However, the goal of imaging receptors using MRI in the clinic 
has been elusive.[20] The most common approaches used to prepare 
macromolecular structures containing Gd3+ chelates involve conjugation of 
functionalized chelates to polymers, dendrimers, or biological molecules. In 
addition, macromolecules with multiple ligands were prepared by polymerization.  
Conjugation methods for linking chelates to macromolecules are well established 
in the literature.[21] Typical chemistries include the functionalization of primary 
amines using acylation, alkylation, ureas or thiourea formation, and reductive 
amination. The majority of papers have been published using commercially 
available reagents, such as DTPA itself or DTPA-dianhydride, to functionalize 
macromolecules. Reaction of these molecules with a reactive primary amine on the 
macromolecule generates an amide bond using one of the DTPA carboxylates. 
Although the number of donor atoms is unchanged,, the donor set has been 
modified as compared with DTPA itself: one acetate donor has been replaced with 
an amide oxygen.  
The advantage over the covalently bound conjugates is that the reversible binding 
implies the constant presence of small amounts of the “free” monomeric complex 
that maintains its typical excretory pathway (elimination through the kidneys), 
thus minimizing the possible toxic effects associated with a long retention time. 
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The noncovalent interaction promotes an increased residence lifetime of the 
contrast agent in the vascular system, making it suitable for  MRI angiographic 
applications. In general, it is well recognized that the relaxivities of the HSA-bound 
complexes (r1b) are significantly lower than those expected on the basis of the 
pronounced slowing down of the molecular motion. Whereas the calculated values 
of r1b  for nearly immobilized complexes are of the order of 100 mM–1 s–1  (20 MHz 
and 298 K), the experimentally measured values fall in the range  12–55 mM–1 s–1.[22] 
Much evidence has been collected that demonstrates that the relaxation 
enhancement of the inner sphere term (r1IS ) is severely limited by a relatively long 
exchange lifetime (τM) of the coordinated water molecule(s). Apart from detailed 
relaxometric studies, the occurrence of a slow-exchange condition is clearly 
illustrated by the good linear correlation between the observed r1b and kex values 
for a series of q = 1 DTPA- and DOTA-like Gd3+ complexes (Figure 1.8).  
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Figure 1.8. top) Correlation between the relaxivity values (20 MHz, 25 °C) of HSA-
bound Gd3+ complexes with q = 1 and their rate of water exchange. Data not labeled 
corresponds to data for DOTA and DTPA derivatives; bottom) DOTA- 
benzyloxymethy derivatives. [Botta M., Tei L., Eur. J. Inorg. Chem. 2012, 1945–1960] 
The higher relaxivity is associated with the faster rate of water exchange, although still 
far from the optimal value, of a Gd–DOTA derivative bearing three pendant benzyl 
groups (Figure 1.8, GdL5).[23] 
Table 1:  Relaxometric parameters of complexes GdL1–GdL5. 
A more thorough analysis of the properties of this latter complex provides important 
insights for further relaxivity enhancement. Let us consider five related derivatives of 
DOTA, containing one, two (two cis isomers and one trans isomer), and three 
benzyloxymethyl substituents, whose basic relaxometric properties have been 
previously investigated. Their r1 values increase from GdL1 to GdL5, simply reflecting 
the increase in τR. The water residence lifetimes, calculated from 17O NMR 
spectroscopic data, are found to be in the range 100– 250 ns, but they do not show a 
clear trend. On the other hand, it is well known that two diastereoisomeric pairs of 
enantiomers  are present in the solution of Ln–DOTA complexes.[24] These are referred 
to as square antiprismatic (SAP or M) and twisted square antiprismatic (TSAP or m) 
forms. Furthermore, the water exchange rates in TSAP isomers of Gd–DOTA 
derivatives are about one order of magnitude faster than those of a SAP isomer. Then, 
the differences in the average or effective τM values found for GdL1–GdL5 are likely 
to reflect a differential distribution of the isomers in each chelate. These distributions 
have been determined from the integration of the low field axial peaks in the 1H NMR 
spectra of the corresponding Eu3+ complexes.[24] Knowing the isomer population 
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makes it possible to fit the 17O data to a sum of the two species, the SAP and TSAP 
isomers. This procedure enabled the extraction of the M values for both the SAP and 
TSAP isomers of each complex, which are the same, within the limits of experimental 
error: M (SAP) = 245.1 ns; M (TSAP) = 41.2 ns. From the data in Table 1, a linear 
dependence of the relaxivity of the HSA-bound complexes on the isomeric ratio is 
evident. It is then possible to calculate the corresponding values of the hypothetical 
single-coordination isomers: r1b (SAP) ≈ 15 mM–1 s–1; r1b (TSAP) ≈ 80 mM–1 s–1.  
 
 
Figure 1.9. NMRD profiles for GdL5 free (.) and bound to HSA (♦). The solid line 
through the experimental data was calculated with the following parameters: Δ2 = 
4.6 x 1018 s–2 , τv = 23 ps, τR = 11 ns, τM = 180 ns, r = 3.1 Å, q = 1. The upper dashed 
curve is the simulated NMRD profile with τM = 41 ns. 
 
This is illustrated by Figure 1.9, which shows the experimental NMRD profile of GdL5 
bound to HSA and the simulated curve with τM = 41 ns. Thus, a careful selection of the 
coordination isomer in DOTA-like complexes may yield relaxivity values for the 
protein-bound adducts close to those predicted by theory. 
In a recent systematic study, Caravan and co-workers have thoroughly investigated 
the properties of 38 Gd– DOTA derivatives and their binding to serum albumin.[25] 
Complexes in this series present a distinct protein-binding moiety and differ in the 
nature of the coordinating arm on one of the macrocyclic nitrogen atoms. At 20 MHz 
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and 310 K, the r1b values were found to be in the range from approximately 12 to 56 
mM–1 s–1. The important results of this report are: (1) it is possible to modulate the 
water exchange rate over three orders of magnitude by the proper choice of the donor 
group (the relaxivities vary accordingly); (2) the second-sphere relaxivity, that is a 
contribution attributable to water molecules hydrogen-bonded to the polar group of 
the chelator, plays a role and accounts for differences in r1b in similar complexes with 
identical donor atoms; (3) fast internal motions limit the relaxivity also in the case of 
complexes characterized by an optimal water exchange rate. In a related study, the 
importance of the second-sphere relaxivity is further highlighted and shown to be 
largely increased by introducing amide groups.[26] 
The presence of internal flexibility along the chain that connects the metal chelate to 
the targeting group represents an important limiting effect on the relaxivity of the 
protein-bound CA even with the optimization of the others parameters. In fact, the 
internal rotation about the linker does not allow the increase in molecular size to 
translate into a proportional decrease in the tumbling motion and hence into a 
relaxivity enhancement. To understand the extent of such an effect on r1b, is possible 
to consider a simple model system consisting of a small and compact Gd3+ complex 
(Gd–NpEGTA) featuring a single fast exchanging bound water molecule, and a rigid 
targeting moiety for HSA binding (Scheme 1).[27] The rigid naphthalene backbone does 
not allow a high degree of local motional freedom, and only very small rotational 
movements of the complex in the binding pocket may take place. As a result, relaxivity 
values very close to those predicted by theory (68 and 78 mM–1 s–1, at 20 and 30 MHz 
respectively) are reported.  
 
Scheme 1. NpEGTA: a naphthalene rigidified EGTA derivative. 
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O
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An important approach has been discussed by Caravan et al., who combined the 
advantages of multimeric Gd3+ agents with two targeting vectors.[28] The idea is that 
two points of attachment help to rigidify the molecule upon binding. A tetrameric Gd–
DTPA-based system was functionalized with two HSA-binding moieties; it showed a 
large relaxivity enhancement (>30 %) as compared to the related agent containing a 
single binding moiety. Multilocus binding greatly reduces the internal flexibility; thus, 
making the complex more rigid and the obtained relaxivity value higher. 
Another successful strategy to enhance the relaxivity is the use of q = 2 complexes. 
Doubling the inner sphere water molecules translates into a doubling of r1IS, the most 
relevant contribution to relaxivity in macromolecular systems. The Gd3+–
hydroxypyridonate (Gd–HOPO) family of contrast agents with q = 2 exhibits optimum 
water exchange rates (τM typically 10 to 20 ns) and high thermodynamic stability 
(Scheme 2). A poly(ethylene glycol) (PEG) moiety of average molecular weight 5000 
Da was attached to the ligand TREN–HOPO–TAM because of the known ability of 
PEG chains to bind to HSA across a wide pH range.[29] The corresponding Gd3+ 
complex was found to weakly bind HSA with a formation constant ka = 186 ± 50 M–1. 
The relaxivity of the protein-bound complex was calculated to be 74 .14 mm–1s–1 (20 
MHz and 298 K), a value considerably higher than those typically reported.[30] More 
recently,  an analogous approach was followed by attaching a long aliphatic chain to 
the AAZTA coordination cage (Gd–AAZTAC17), that will be described in the next 
paragraph.[31] 
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Scheme 2. HOPO and AAZTA derivatives. 
This complex (q = 2 and τM = 67 ns) was found to have a higher affinity for fatted HSA 
than for defatted HSA, whereas the relaxivities of the macromolecular adducts were 
reversed. The relaxivity of the defatted-HSA bound complex (r1b= 84 mM–1 s–1 at 20 
MHz and 298 K) is the highest value reported so far for noncovalent paramagnetic 
adducts with slow-tumbling substrates. 
 
1.4.2 Nanosized lipidic systems 
 
Paramagnetic micelles have often been considered as contrast agents for MRI 
applications [32]. These molecules form aggregates in which the hydrophobic portions 
are oriented within the cluster and the hydrophilic moieties (containing the Gd-probe) 
are exposed to the solvent. Depending on the length and the number of hydrophobic 
chains and on the nature of the hydrophilic heads, the obtained micelles are 
characterized by different size and shape (spherical, cylindrical, vesicular). The 
observed relaxivities (expressed as mMGd-1 s−1 are basically determined by the number 
(q) of water molecules in the inner coordination sphere of the paramagnetic metal ion. 
In fact, almost all the q = 1 systems have relaxivity values in the range 18–23 mMGd-1 
s−1 and the q = 2 systems 29 mMGd-1 s−1. Basically, the relatively low relaxivity values 
shown by the paramagnetic micelles depend on the non-optimal dynamic regime of 
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these systems, which is characterized by the occurrence of a fast local motion of the 
Gd-containing cage at the surface of the micelle overlapped to a slower global motion 
of the supramolecular aggregate. 
An accurate determination of the parameters governing the reorientational dynamic 
may be pursued through the quantitative analysis of the NMRD (Nuclear Magnetic 
Relaxation Dispersion) profiles. The fitting procedure of the NMRD profiles of Gd-
based micelles is frequently performed by using the Solomon–Bloembergen–Morgan 
equations modified according to the model-free approach developed by Lipari and 
Szabo for non-extreme narrowing conditions [33,34]. This approach allows to distinguish 
between a local faster motion (governed by Rl) and a global slower motion (governed 
by Rg).  
 
 
 
 
1.4.2.1 Self-assembling aggregates of amphiphilic Gd(III) complexes  
 
Amphiphilic Gd-complexes consist of a chelating agent covalently bound to one or 
more hydrophobic moieties such as long alkyl chains or organic residues that 
promotes the aggregation process in a water-based solution. Generally, the kind of 
aggregate obtained by self-assembly of amphiphilic Gd-complexes without the use of 
external molecules are micelles. In micelles, the Gd3+ complexes are exposed to the 
hydrophilic exterior spacewith easy access of the bulk water to the paramagnetic 
center. 
The structural properties of the hydrophobic chain such as its length and its nature can 
influence the stability, the size and the aggregation number of monomers in the 
micelle. Moreover, the relaxivity behaviour of micelles can dramatically change as a 
function of the hydrophobic moiety. 
Several studies were carried out on amphiphilic chelating agents in order to determine 
the most accurate mathematical approach to study the rotational dynamics of the 
aggregates, and to justify the relaxivity values. Between 1999 and 2002, Merbach and 
co-workers[35,36] described the synthesis and relaxometric characterization of five 
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potential Gd3+-based MRI contrast agents which are capable of micellar self-
organization. They mainly differ in the length of their side chain, varying from 10 to 
18 carbon atoms.  
 
 
Scheme 3: GdDOTA-like amphiphilic complexes studied by Merbach and 
coworkers. 
 
Three of them, [Gd(DOTAC10)(H2O)]–, [Gd(DOTAC12)(H2O)]– and 
[Gd(DOTAC14)(H2O)]– are DOTA-like chelates bearing an alkyl chain with 10, 12 and 
14 carbon atoms. The other two, [Gd(DOTASAC12)(H2O)] and 
[Gd(DOTASAC18)(H2O)] have a DOTA chelating unit and a monoamide-dodecyl or a 
monoamideoctadecyl carbon side chain, respectively (Scheme 3). As stated above, for 
the analysis of the longitudinal 17O and 1H relaxation rates of the aggregates, the 
authors used the Solomon–Bloembergen–Morgan model, modified according to the 
Lipari–Szabo approach. The relaxivity values of the five micellar systems are reported 
in Table 2. 
 r1  (mM-1 s -1) 
Gd-DOTAC10 9.3 
Gd-DOTAC12 17.2 
Gd-DOTAC14 21.5 
Gd-DOTASAC18 20.7 
Gd-DOTASAC12 18.0 
 
Table 2: relaxivity values of the five micellar systems reported in Scheme X 
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NN
-OOC COO
-
COO--OOC
Gd3+
R
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O
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It is interesting to underline that the relaxivity increases with increasing chain length 
within the series, with the exception of [Gd(DOTASAC18)(H2O)]−. This effect can be 
explained by the different rotational motions (global and local) and by the model-free 
parameter S2 of the five systems. As expected, the global rotational correlation time, τg, 
increases with increasing length of the side chain (τg = 1600, 2220, 2810 ps, for 
[Gd(DOTAC12)(H2O)]–, [Gd(DOTAC14)(H2O)]–, [Gd(DOTASAC18)(H2O)]–, 
respectively). On the other hand, the local motions, that are also influenced by length 
and the hydrophobicity of the side chain, do not follow the expected behaviour: in fact 
in [Gd(DOTASAC18)(H2O)]− micelles the additional amide function, prevents strong 
hydrophobic interactions between the long chains and reduces its internal flexibility 
(short τl value and low S2 ). 
 
Scheme 4: Some amphiphilic Gd3+ complexes. 
 
The relaxivity value of the supramolecular aggregate is influenced not only by their 
hydrophobic moiety, but also by the chelating agent on the head-group. For example, 
the relaxivity value strongly increases from 18.0 to 29.2 mM−1s−1 by replacing  DOTA-
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like ligands with PCTA [37], a q = 2 chelate, notwithstanding the two monomers Gd-
PCTA-[C12] and DOTASAC12 (indicated in Scheme 3 and 4) have the same 
hydrophobic chain, the same coordination geometry on the gadolinium ion and 
aggregation properties (micelles with a similar critical micellar concentration in the 
1.5–3.4 × 10−4 M range). This means that the enhancement in terms of relaxivity is 
mostly ascribable to the increase of the number of inner sphere coordinated water 
molecules. 
 
 r1  (mM-1 s -1) 
Gd-PCTA[12] 29.2 
Gd-AAZTAC17 30.0 
Gd-EPTPA-C16 22.6 
 
Table 3: relaxivity values of the micellar systems represented in Scheme 4. 
 
Clearly the micellization of amphiphilic gadolinium complexes gives rise to a system 
with slower molecular tumbling with respect to the monomeric complex, but the 
resulting relaxivity appears still lower than the expected values as internal motions are 
faster than the overall tumbling of the micellar system. Merbach and coworkers 
proposed that interactions between nearby paramagnetic centers in micellar systems 
increase the transverse electronic relaxation of the electronic spin of Gd3+ and, 
therefore, reduce the attainable water proton relaxivity [38]. This drawback can be 
removed by diluting the Gd3+ ions with diamagnetic Y3+ ions in order to increase the 
distance between the neighbouring Gd3+ ions. This theory was also recently confirmed 
by Aime et al. for micellar aggregates obtained by self-assembling of the Gd-
AAZTAC17 amphiphilic gadolinium complex 7. They studied how the relaxivity value 
of micellar aggregates of Gd-AATZAC17 (30.0 mM−1 s−1) changes when 98% of the 
Gd3+ complexes on the external surface of the micelles is replaced by the corresponding 
Y3+ complexes. The result observed was an enhancement in relaxivity of around 40% 
over the entire frequency range (41.4 mM−1 s−1 at 20 MHz [39]. 
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In 2006 Geraldes et al. [40] reported an “in vitro” characterization and “in vivo” animal 
imaging studies on self-assembling micelles of Gd-EPTPA-C16 monomer. The in vivo 
results were compared with the commercially available low molecular weight 
Magnevist® [41]. The critical micellar concentration (3 × 10−4 M) of the amphiphilic 
[(Gd-EPTPA-C16)(H2O)]2− chelate was determined by variable-concentration proton 
relaxivity measurements. The rotational dynamics of the micelles, analyzed by using 
the Lipari–Szabo approach, suggested that micelles formed in aqueous solution show 
considerable flexibility, with a local rotational correlation time of  τl = 330 ps and a 
global rotational correlation time τg = 2100 ps. These values are in good agreement 
with the results above described for the five compounds reported in Scheme 3. The in 
vivo evaluation of the micellar [Gd(EPTPA-C16)(H2O)]2− compound in Wistar rats 
shows a persistent hepatic positive-contrast effect in T1-weighted images, which is 
qualitatively similar to that of the clinically established Gd3+-based hepatobiliary 
agents, Gd-EOB-DTPA [42] and Gd-BOPTA [43]. The possibility of using this type of 
micellar compound for imaging disease depends on the degree of stability of the 
imaging agent in the body relative to its critical micellar concentration. The 
amphiphilic gadolinium complexes above described have only one hydrophobic 
chain. Critical micellar concentration of mono-tailed surfactants is usually in the range 
of 0.1–0.01 mM. Upon dilution in the blood following injection, these aggregates may 
not be sufficiently stable and disassemble immediately following administration. 
Hence, there is a need to find a new class of surfactant molecules able to form more 
stable micelles with lower critical micellar concentration values. One of the possible 
candidates for this role, can be represented by aggregates obtained by self-assembling 
of monomers with two or more alkyl chains. 
Recently, Paduano et al. reported supramolecular aggregates, constituted basically by 
the DTPAGlu moiety bound to a hydrophobic double-tail (18 carbon atoms), [43]. The 
amphiphilic molecule behaves as an anionic surfactant, and is capable of forming 
aggregates of different sizes and shapes (rodlike micelles, threadlike micelles, and 
vesicles) in aqueous solution by varying the method of preparation and the 
environmental conditions such as pH and ionic strength. A micelle-to-vesicle 
transition was observed by decreasing the pH value from 7.4 to 3.0; and/or by 
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increasing the ionic strength. Relaxivity values of Gd-(C18)2DTPAGlu aggregates at 
pH 7.4 in the presence and absence of NaCl at physiological ionic strength were 21.5 
and 24.0 mM−1 s−1 , respectively [44,45]. 
 
Scheme 5. Some DOTA- and DTPA-like Gd3+ amphiphilic complexes. 
 
An alternative approach to prepare physiologically stable aggregates include the use 
of Gd-labelled polymerized liposomes, prepared by using a polymerizable 
amphiphilic Gd–DTPA derivative [46]. 
In the literature there are few examples of supramolecular aggregates obtained also by 
starting from amphiphilic Gd-complexes in which the hydrophobic moiety is not 
represented by an alkyl chain, but from an organic molecule such as cholic acid. 
In 2003 Lattuada et al. reported the synthesis of Gd-DTPA-Chol. Its relaxivity value in 
water (27.2 mM−1 s−1 ), extremely high compared to the relaxivity of the Gd-DTPA (3.7 
mM−1 s−1 ), is an indirect evidence of micellar self-organization [47]. In 2006 Jorgensen 
et al. synthesized and studied the relaxometric behaviour of another cholesterol-based 
Gd-complex, Gd-DOTA-Chol, in which the chelating agent is represented by a DOTA-
monoamide. This complex was designed to be easily embedded into the membrane of 
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standard cationic liposomes in order to develop a liposome cell labelling system, 
which would be amenable to labell a variety of cells, and could serve other purposes 
such as delivery of plasmid DNA or other nucleic acid derived therapeutics. The 
relaxivity of Gd-DOTAMA-Chol (4.42 mM−1 s−1, 298 K and 20 MHz) is in the same 
order of values of the clinically used Dotarem (5.25 mM−1 s−1, 298 K and 20 MHz), thus 
indicating the Gd-DOTAMA-Chol is unable to self-aggregate [48]. The uncapability of 
Gd-DOTAMA-Chol to self-aggregate can be ascribed to the lack of anionic charges on 
the complex that reduces the amphiphylic character of the complex. 
 
Figure 1.10. The design of the high sensitivity MR-imaging reporter. (a) The binding 
of the supramolecular adduct at the cell membrane through the intermediation of 
the cationic linker is validated by the confocal microscopy images obtained by using 
a Gd-containing nanoparticle doped with a rhodamine-phospholipid and 
polyarginine. (b) MRI of cellular pellets in agar. The cells labeled with 
polyarginine/Gd-nanoparticles (right) contains approximately 6 × 109 Gd per cell 
and display a T1 value of 334 ms to be compared with a T1 of 2064 ms of the 
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unlabeled cells (left). [D. Delli Castelli et al. / Coordination Chemistry Reviews 252 
(2008) 2424–2443] 
 
 
Another interesting system, developed by Aime and co-workers, consists of self-
assembled lipophilic Gd-AAZTA(C16)2 complexes (Figure 1.10) interacting with the 
cell-surface labelled with cationic polyarginine. . The presence of two long aliphatic 
chains and the aromatic moiety endowed this amphiphilic complex with a very high 
tendency to aggregate in aqueous media. Already at monomer concentration as low as 
1 × 10−5 M the system appears to be present in an aggregated form (likely discoidal 
aggregates) characterized by a relaxivity of 25 mMGd-1 s−1 at 298 K and 20 MHz, a 
diameter of ca. 80 nm (with a very low polydispersity index) and an aggregation 
number of ca. 850. 
 
 
 
 
 
 
1.4.2.2 Lipid nanoparticles: micelles 
 
Another class of supramolecular aggregates containing amphiphilic Gd-complexes 
could be obtained by their co-assembling with one or more commercial surfactants 
such as phospholipids, non-ionic surfactants or cholesterol. Classical phospholipids 
can be divided in saturated (DPPC, DSPC, DSPE) and unsaturated (DOPC, POPC) 
molecules. 
The most common components of phospholipids are phosphatidyl choline (PC), 
phosphatidyl glycerol (PG) and phosphatidyl ethanolamine (PE). Generally, the 
presence of phospholipids within the supramolecular aggregate favours the formation 
of bilayer structures such as vesicles or liposomes. One of the first examples of 
supramolecular aggregates obtained by amphiphilic Gd-complexes mixed to 
phospholipids was reported in 1992 from Elgavish et al. They synthesized several 
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amphiphilic Gd-complexes based on DTTA ligand (DTTA = 
diethylenetriaminotetraacetic acid; 1MP-DTTA; 4MP-DTTA; 4MPD-DTTA; BME-
DTTA) and studied the in vitro relaxometric behaviour and the in vivo properties of 
mixed liposomes as potential contrast agents for MRI of myocardial under-
perfusion[49,50–52]. For example, Gd-BME-DTTA (Scheme 6) was obtained by 
conjugating the DTTA chelating moiety to two long fatty myristoyl chains. Because of 
its limited solubility in water, Gd-BME-DTTA complex was incorporated into egg 
lecithin liposomes.  
 
 
Scheme 6.  
The median lethal dose (LD50) of liposomal Gd-BME-DTTA formulation in mice was 
of 0.56 ± 0.05 mmol/kg and no deleterious effects on heart rate, blood pressure, left 
ventricular force and AV conductance in ferret hearts in vivo at the magnetic resonance 
imaging effective dose of 0.05 mmol/kg body weight were detected. In MRI images, a 
-OOC N
-OOC
N
O
O O
N
O
O
N
-OOC
-OOC
OGd3+
Gd-BME-DTTA
N N
NN
-OOC COO
-
R-OOC
Gd3+ Gd-HDD-DO3A1R=
2R=
OH
OH
R =
R =
R =
Gd-DTPA-BC14
Gd-DTPA-BC16
Gd-DTPA-BC18
N N N
-OOC
-OOC
CONHR
COO-
Gd3+
COO-
R =
R =
R =
R =
Gd-DTPA-MC14
Gd-DTPA-MC16
Gd-DTPA-MC18
Gd-DTPA-MC12
N N N
-OOC
COO-
COO-
NHR
O
Gd3+RHN
O
34 
 
1H signal intensity enhancement was observed in the following organs in decreasing 
order of the effect: heart ≈ spleen > kidney > liver. This enhancement remained stable 
for over 3 h in all organs. Moreover, the incorporation of Gd-BME-DTTA in liposomes 
produced an increase of the in vitro relaxivity of the contrast agent up to 27.0 mM−1 s−1 
. In anyway, the relaxivity of a liposomal Gd-BME-DTTA sample, stored at 4◦ C, 
remained stable for over 4 months of observation, but a significant decrease in 
relaxivity (8.2 mM−1 s−1 after 40 days) was observed in a sample stored at room 
temperature. The observed time-dependent reduction in relaxivity can be possibly 
attributed to the dissociation of Gd-BME-DTTA from the phospholipid bilayer. Thus, 
liposome stability and relaxivity properties of the aggregate over the time are strongly 
related to the incorporation degree of amphiphilic gadolinium complex in the 
liposome membrane. 
At this purpose, in 2000 Gløgård et al. investigated the effect on the relaxivity of several 
parameters including the incorporation degree of the Gd3+ amphiphilic chelates on the 
membrane packing. They studied mixed liposomes formulated by using several 
phospholipid molecules (DMPC, DPPC, DSPC, DMPG, DPPG, DSPG) in which two 
amphiphilic Gd-HPDO3A-like derivatives were alternatively introduced [53]. Gd-
HDD-DO3A and Gd-HHD-DO3A (Scheme 5) were synthesized by functionalizing 
DO3A chelating agent with hydroxydodecyl and hydroxyhexadecyl moieties, 
respectively. In the different formulations, the amount of cholesterol and the type of 
Gd-chelate, were varied between 0–40 and 1–10% mol/mol, respectively. The 
incorporation efficacy seems to be directly correlated to the lipophilic moiety of the 
chelates. In fact, Gd-HHD-DO3A, with the highest partition (P) coefficient between 1-
octanol and water, was completely incorporated whereas an incorporation efficacy 
between 12 and 23% was observed for the less lipophilic Gd-HDD-DO3A. Moreover, 
larger liposomes showed only a minor positive effect on the incorporation efficacy, 
while the cholesterol content has no effect on the Gd-chelate loading [54]. In contrast to 
the expected results, the relaxivity value decreased with the increase of incorporation 
degree of Gd-complex maybe due to the negative influence of the Gd-chelate on the 
membrane packing . Likely, the impact of this effect is an increase in the lateral surface 
motion on the liposome surface, leading to a shortening of τR for the Gd-chelates and 
thereby a decrease in the relaxivity. The same authors also reported on the influence 
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of the cholesterol content on the structure and relaxivity of aggregates obtained by Gd-
HHD-DO3A [55]. 
The incorporation degree of amphiphilic Gd-complexes in liposomes represents only 
one of the numerous parameters that can play an important role in the relaxometric 
behaviour of liposomes. The mobility degree of the amphiphilic Gd-complex depends 
on the length and on the position of the alkyl chains on the Gd-complex. In this contest, 
Binnemans et al. between 2003 and 2006 reported the synthesis of three different sets 
of amphiphilic derivatives of DTPA with alkyl chains of different length. The Gd-
complexes of these ligands were incorporated into mixed aggregates of DPPC 
phospholipid and Tween 80 to obtain supramolecular structures. In the first set, the 
amphiphilic Gd-complexes are represented by DTPAbisamide derivatives with alkyl 
chains containing 14, 16 and 18 carbon atoms (Gd-DTPA-BC14, Gd-DTPA-BC16 and 
Gd-DTPA-BC18 (Scheme 5) [56]. In the second set, DTPA-bisamide derivatives were 
replaced by the DTPA-monoamides (Gd-DTPA-MC12, Gd-DTPA-MC14, Gd-DTPA-
MC16 and Gd-DTPA-MC18, Scheme 5) [57]. Finally, in the last set the DTPA-bisamide 
derivatives were modified by introducing aromatic side chain groups (DTPA-BPT; 
DTPA-BPH and DTPA-BPO, Scheme 6) [58]. By comparing τM and τR values of the three 
sets of aggregates resulted that the relaxivity values of mixed aggregates incorporating 
monoamide complexes were higher than aggregates incorporating bisamide 
compounds with analogous chain length. Both τM and τR values of Gd-DTPA-MCn 
monoamide supramolecular aggregates were smaller than those of Gd-DTPA-BCn 
and Gd-DTPA-BPX. Indeed it is well known that Gd-DTPA derivatives with amide 
groups are characterized by a decreased exchange rate of the coordinated water 
molecule and that τM is related to the number of amide functions and their 
substituents[59]. On the other hand the τR values decreased as a consequence of a more 
efficient immobilization of the paramagnetic part of the bisamide derivatives caused 
by the incorporation of both hydrophobic chains into the micellar or liposomal 
membrane. These smaller τR values were not followed by a decrease but by an increase 
in relaxivity because of the smaller τM values.  
 
The immobilization of bisamide derivatives at eighteen carbon atoms (Gd-DTPA-BC18 
and Gd-DTPA-BPO) inside the supramolecular structure was less effective, probably 
36 
 
because the aliphatic chains of the complex were longer than the alkyl chains of DPPC, 
in which it was inserted, resulting in a relatively high local mobility. The 
corresponding paramagnetic aggregates with 14 carbon atoms chains DTPA-BPT 
showed the highest relaxivity, most likely because the optimal length match between 
the hydrophobic chains of the DPPC and the amphiphilic Gd-complex allowed very 
efficient packing of the paramagnetic complex into the aggregate. Mixed micelles 
incorporating Gd-DTPA-MC12 amphiphilic monomer show a relaxivity value (5.0 
mM−1 s−1 ) more similar to its parent compound Gd-DTPA than the supramolecular 
aggregates. It can be explained by comparing the τR values obtained for the Gd-DTPA-
MC12 (0.105 ns) in the micellar solution with respect to those of the other complexes 
of the series (0.91–1.12 ns). This result indicates that this complex is either very loosely 
incorporated inside the micellar membrane or not incorporated at all.  It was suggested 
that the aliphatic chain of this complex was too short and the hydrophobic character 
of the complex too low to allow efficient incorporation into the micellar structures. 
Finally, the same authors studied a compound (Scheme 7), Gd-DTPA-BC18Aunsat, 
containing one C=C double bond in each of the two lipophilic chains[60]. The presence 
of the unsaturations, as reported above, increased the flexibility inside the membrane 
layers and the water permeability, thus increasing relaxivity. 
 
Scheme 7 
  
Another factor influencing relaxivity is represented by the membrane composition of 
aggregates, such as the saturation level of membrane, the transition phase temperature 
of phospholipids and the cholesterol content. As above reported, Gd-complexes 
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incorporated in liposome bilayer can distribute on both sides of the phospholipidic 
membrane and the two contributions arising respectively from the complexes in the 
inner and in the outer layers have to be considered. The two contributions depend 
from liposome membrane permeability which is strictly related to the bilayer 
composition (saturated or unsaturated phospholipids). Liposomes obtained with 
saturated phospholipids present a lower membrane permeability with respect to those 
made by unsaturated phospholipids[61,62]. The reason for such a behaviour is the 
different packing of the hydrophobic chains in the bilayer. The presence of an 
unsaturation in the hydrocarbon chain reduces the tightness of the bilayer assembly, 
thus facilitating the water flux across the bilayer and improving the relaxivity. When 
the liposome membrane permeability is high, the water exchange is extremely fast and 
both the complexes in the inner and in the outer layer contribute to the observed 
paramagnetic relaxation rate[63]. On the contrary, if the membrane permeability is low, 
water exchange rate through the membrane is very slow and the main relaxation effect 
is due to the complexes exposed to the external media. This theory was very recently 
confirmed by Muller et al. who compared the relaxometric behaviour of two 
unilamellar liposomes (DPPC/Gd-DTPA-BC14 = 10/1), incorporating Gd3+ 
amphiphilic complexes either in their external and internal layers or only at the 
external one. Mixed liposomes with Gd-complexes located only in the external part 
were successfully obtained by transmetallation of La3+ by Gd3+ ions of DPPC/La-
DTPA-BC14 liposomes. The relaxivity of these liposomes (16.98 mM−1 s−1) is increased 
as compared to that of the liposomes containing the complex in both sides of the 
membrane (9.86 mM−1 s−1 ), thus indicating that the complexes located in the internal 
layer contributes less to the global relaxivity[64].  
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Scheme 7. 
The water permeability (PW) of liposomes can also be strongly influenced by the 
incorporation of amphiphilic Gd-complexes in the lipid bilayer, as reported by Aime 
et al. Two liposome formulations (DPPC/DSPE-PEG2000 and POPC/Chol/DSPE-
PEG2000) were selected in order to compare the variation of PW between the saturated 
and unsaturated liposomes. The amphiphilic complexes used for the experiments 
(Scheme 7) were previously proposed by Lattuada et al. as a new class of stable blood 
pool MRI/MRA contrast agents after incorporation in mixed aggregates[65,66]. The 
incorporation in DPPC-based liposomes of LaL1 complex, bearing two saturated C18 
chains, did not affect so much the water permeability of the membrane, while the 
incorporation of LaL2 complex (Scheme 7), bearing one saturated C12 chain for each 
coordination arm of the chelate, significantly accelerated the water mobility across the 
membrane. This result suggests that the incorporation modality adopted by the latter 
amphiphilic compound destabilizes the compact packing of the DPPC bilayer. 
On the other hand, when the amphiphilic complexes are incorporated in unsaturated 
liposomes (POPC-based liposomes) a stabilization of the aggregate occurs and the 
water permeability of the membrane decreases proportionally to the amount of the 
incorporated compound[67].  
Another extremely important parameter influencing the relaxivity is represented by 
the transition phase temperature. Liposome bilayers present a liquid-crystalline state 
and a high water exchange rate between the interior and exterior liposome 
comparments, allowing bulk water to experience magnetic interaction with the Gd-
chelates located on the inner surface. On the contrary, liposome bilayers in the solid–
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gel state have a low water exchange rate, making the inner surface chelates less 
accessible for the bulk water and thereby decreasing their contribution to the overall 
relaxivity[49]. Also the lateral motion on the liposome surface is about twice as high in 
a liquid-crystalline membrane compared to a gel state membrane[68]. This should give 
rise to a longer τR for the Gd-chelates incorporated into a gel state-membrane with 
respect to complexes incorporated in liquid-crystalline state, thereby increasing their 
relaxivity. 
The cholesterol introduction in the formulation has always a positive effect on the 
relaxivity. The influence of cholesterol on the liposome membrane is associated to the 
phase transition temperature of the latter. With its incorporation into a solid–gel 
liposome cholesterol fluidises the membrane, leading to increased transmembrane 
water permeability and hence to an increased relaxivity of the Gd-chelates present 
inside the liposomes. In liquid-crystalline liposomes, the positive effect of cholesterol 
incorporation is most likely related to an increase in the membrane rigidity leading to 
an increase of the rotational correlation time (τR) of the Gd-chelate. According to these 
considerations, the highest relaxivity was obtained for DMPC-based liposomes (24–42 
mM−1 s−1 ) compared to the DSPC-ones (20–28 mM−1 s−1 ). According to Gløgård 
assumption, Strijkers et al. verified that unsaturated lipidbased liposomes 
(DOPC/DSPE-PEG2000/Gd-DTPABSA) have higher relaxivity with respect to 
liposomes based on saturated phospholipids (DSPC/DSPE-PEG2000/Gd-
DTPABOA), and the adding of cholesterol leads to a further, although smaller, 
increase of the relaxivity[69]. 
Moreover, Aime et al.[70], proposed systems based mixed liposomes in which Gd-
complexes are conjugated to phospholipids by a disulfide bond, that is sensitive to the 
presence of radicals: when the disulfide bond is cleaved upon radical attach the T1-
relaxivity of the system decreases to give the r1 value of the free Gd chelate. 
Nowadays, the research is devoted to find new multifunctional liposomes, able to 
address at the same time two or more targets, such as pDNA transfection or diagnosis 
and treatment of diseases. For example, in the last year Miller et al. reported bimodal 
paramagnetic and fluorescent liposomes both for in vitro cell labelling and in vivo 
tumour imaging [71]. The amphiphilic Gd-DOTA·DSA complex (Scheme 7) and a small 
amount of the fluorescent lipid DOPE-Rhodamine (0.5–1.0 mole%)were incorporated 
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in DOPC/Chol/DSPE-PEG2000 liposomes. This method permits to quantify uptake 
and internalization of liposomes into cells. Liposomal surface was also modified with 
PEG chains to prolong their circulation time in the body[72]. In fact, surface 
modification with PEG polymers produces changes in biodistribution and body 
retention of liposomes preventing their opsonisation by macrophages[73-75].  
 
1.4.2.3 Lipid nanoparticles: Liposomes  
 
Liposomes are nanosized vesicles in which an aqueous core is encapsulated by one 
(unilamellar) or more (multilamellar) phospholipidic bilayers. A further sub-
classification divides the unilamellar vesicles (UV) in small (SUV, diameter of 50–150 
nm) and large (LUV, 150–800) liposomes according to their size. As soon as they were 
discovered [76], it was immediately recognized the great relevance that such systems 
could have in the biomedical field as model systems for studying biological 
membranes and as drug carriers. As far as concern the latter application, the main 
strong points in favour of liposomes are: (i) high biocompatibility, (ii) easiness of 
preparation, (iii) possibility to carry hydrophilic, amphiphilic and lipophilic 
molecules, (iv) possibility of modulating the pharmacokinetic properties by changing 
the chemical composition of the bilayer. In addition to all these properties that make 
liposomes excellent nanocarriers for MRI applications, they can also  greatly improve 
the contrastographic efficiency of the transported agent.  
The first reports about the use of liposomes loaded with T1-shortening MRI agents 
were published in the late 1980s and dealt with the encapsulation of high amounts 
(hundreds of millimolar) of hydrophilic paramagnetic ions as Mn2+ [77] or Mn2+- and  
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Figure 1.13. r1 relaxometric pH dependence of dipalmitoylPE/DPGS liposomes 
encapsulating Gd-DTPA-BMA containing 10 mol% (filled squares) and 30 mol% 
(upper triangles) of DPSG, and distearylPE/DPGS containing 10 mol% of DPGS 
(open circles) after 20 min of incubation in buffered human whole blood (0.47 T, 310 
K). Adapted from ref. [84]. 
 
Gd3+-complexes [78-81] in the aqueous core of the vesicle. The resulting paramagnetic 
vesicles were mainly used as carriers for the delivery of the imaging agents to 
pathological tissues, mostly tumors, where the liposomes are expected to passively 
accumulate thanks to the Enhanced Permeability and Retention (EPR) mechanism 
[82,83].  
The successful MRI visualization of several tumors on animal models (including the 
detection of liver metastasis) after the i.v. injection of T1-shortening liposomes is 
primarily the result of the high relaxivity of the nanosized vesicles that carries 
hundreds of thousands of imaging reporters. However, it is worth noting that the 
relaxation enhancing efficacy of a single imaging reporter is considerably “quenched” 
when it is encapsulated in the liposome. As an illustrative example, the millimolar 
relaxivity of the clinically approved Gd-HPDO3A complex decreases of about one 
order of magnitude from 3.75 mMGd-1 s−1 to 0.3 mMGd-1 s−1 (values measured at 0.47 T 
and 310 K) when the imaging reporter is entrapped in the liposome cavity [81]. It has 
been demonstrated that this “quenching” effect is inversely proportional to the water 
permeability of the liposome bilayer and to the size of the vesicle, and it is directly 
dependent on the concentration of the paramagnetic system inside the vesicle. 
The relaxivity “quenching” caused by the encapsulation of the imaging reporter has 
been exploited for designing responsive agents in which the water permeability of the 
bilayer or the overall integrity of the vesicles is made sensitive to physicochemical 
variables of theragnostic relevance. Two representative examples can be found in the 
classes of pH and temperature responsive agents. In the former case, the imaging 
reporter is encapsulated in liposomes whose bilayer contains components that change 
their structure (and charge) as a function of pH. A typical combination of amphiphiles 
that confer to the bilayer a pH-responsiveness tuned at the physio-pathological values 
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is represented by phosphatidylethanolamine (PE)-based phospholipids and 
dipalmitoylglycerosuccinate (DPGS).  
 
As far as the temperature reporters is concerned, liposomal MRI probes able to switch 
on the T1 contrast in a narrow temperature range were designed by selecting 
phospholipides with a well-defined gel-to-liquid crystalline transition phase 
temperature (Tm), like distearylphosphatidylcholine (DSPC, Tm ~329 K) or 
dipalmitoylphosphatidylcholine (DPPC, Tm ~314 K) [85]. At temperature higher than 
Tm the liposome bilayer increases its fluidity as well as the water diffusivity and thus 
the relaxivity..  
 
Figure 1.14. Temperature dependence of the relaxivity for Gd-DTPA-BMA free 
(squares) and encapsulated in DSPC-based liposomes (circles). The vertical dashed 
line indicates the Tm value of the bilayer. Adapted from ref. [86]. 
 
In addition, also the stability of the vesicle decreases and the consequent release of the 
encapsulated imaging reporter accounts for the observed relaxivity enhancement.  
Figure 1.14 reports the comparison between the temperature dependence of the 
relaxivity of Gd-DTPA-BMA free and encapsulated in DSPC-based liposomes [80]. The 
data highlights the relaxivity “quenching” occurring at T < Tm due to the low water 
permeability of the DSPC bilayer, and its increase when the temperature is 
approaching the phase transition temperature. This temperature-sensitive liposomal 
MRI agent was also successfully tested in vivo with the aim at guiding hyperthermia 
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ablation in a tumour model on rabbit liver [86]. Figure 1.15 reports a series of T1w MR 
images obtained during the localized RF heating of the tumour (indicated by a white 
arrow), which clearly indicate the appearance of a bright region in the surrounding of 
the treated lesion caused by the release of the Gd3+ chelate from the temperature-
sensitive liposomal agent. 
A more exhaustive list of examples illustrating the great potential of the so called 
thermosensitive liposomes (TSL) for guiding heating-based therapies is reported in the 
review by Lindner et al. [87]. An improvement of the potential of TSL has been recently 
reported by Terreno et al., who proposed a method, based on the measurement of the 
ratio between the paramagnetic contributions to the transverse (R2p) and the 
longitudinal (R1p) relaxation rates, which allows of the idenpendent evaluation of the 
actual concentration of TSL [88]. 
 
Figure 1.15. T1w MR images of RF ablation in rabbit liver after i.v. injection of the 
liposomal contrast agent at different steps: prior heating (t0), during heating (t1), 
after normalization of tissue temperature (t2), and 15–20 min after normalization of 
tissue temperature (t3). Note the increasing of the signal intensity in the periphery 
of the lesion (white arrow). Adapted from ref. [86]. 
 
In principle, the improvement of the T1-relaxing efficiency of liposomes encapsulating 
the imaging reporter can be pursued by using small sized vesicles (SUV) endowed 
with high water permeability, but, unfortunately, the increase of the water diffusivity 
of the membrane is usually accompanied with a significant decrease of the in vivo 
stability of the liposome.  
An alternative approach consists of designing liposomes in which the imaging reporter 
is incorporated in the vesicle bilayer. The relaxivity enhancement of the incorporated 
probe with respect to the encapsulated one relies on the lengthening of the 
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reorientational correlation time, τR, of the former system, that improve the efficiency 
of the dipolar coupling between the unpaired electrons of the paramagnetic ion and 
the water protons. Since this coupling varies as a function of the magnetic field 
strength, the NMRD profiles of liposomes incorporating Gd3+-complexes are 
characterized by the typical relaxivity hump, centred at about 1 T, usually observed 
for slow-tumbling paramagnetic systems [89,90]. The relaxation enhancement of 
liposomes incorporating Gd3+-complexes is determined by the structural and dynamic 
properties of the coordination cage of the metal complex. The most relevant parameter 
is the water exchange rate, kex, of the metal coordinated water that has to be finely 
tuned in order to maximize the overall relaxivity of the system. It has been calculated 
that kex values of 108 to 109 s−1 are optimal to achieve high relaxivities [91]. Two routes 
have been followed for conjugating the lipophilic chains to the coordination cage of 
the metal complex: (i) through the formation of amide bonds involving the carboxylic 
groups of the acyclic ligand DTPA, and (ii) through linkages that minimize the 
chemical characteristics of the donor atoms of macrocyclic (DOTA-based) ligands. The 
first approach has been extensively used, mainly for the relative easiness in the ligand 
synthesis, but it has two major disadvantages: (i) the thermodynamic and kinetic 
stabilities of DTPA amides appear too low for the set-up of safe in vivo applications as 
those required in typical Molecular Imaging protocols[92], and (ii) the kex values for this 
type of coordination cage is much lower than optimal (≤106 s−1 ), thus “quenching” the 
relaxivity attainable with these nanoprobes. Conversely, DOTA-like macrocyclic 
structures, besides a much higher chemical stability, display kex values closer to the 
optimum, even if one of the carboxylate groups is functionalized with the lipophilic 
tail/s through an amidic bond. Support to this view is nicely gained by comparing the 
relaxivities measured at 0.47 T for the membrane incorporated Gd3+-complexes of bis-
stearylamide DTPA (ranging from 8 to 12 mMGd-1  s−1 depending on temperature and 
liposome formulation) [93,94] and for the corresponding systems incorporating the 
amphiphilic DOTA-based compounds (from 25 to 45 mMGd-1  s−1) [90,95]. 
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Liposomes incorporating Gd3+-complexes have been successfully used in many in vivo 
MRI applications on animal models including the visualization of tumors either by 
passive [93] or active [96,97] targeting (Figure 1.16), detection of atherosclerotic plaques 
[98], lymph nodes [99], inflammation sites [100], and visualization of myocardium 
infarcted areas [101]. 
 
Figure 1.16. MR images on a xenografted tumor animal model before (left image) 
and after (middle image) injection with paramagnetic liposomes targeting a neo-
angiogenesis marker (αvβ3 integrin) and incorporating a Gd3+-complexes. Pixels in 
tumor with signal enhancement of at least 5 times the noise level were color coded 
(right image). Adapted from ref. [97]. 
 
Interestingly, the selective tumor distribution of paramagnetic liposomes targeting an 
angiogenesis marker (αvβ3 integrin) has been recently exploited for in vivo monitoring 
the therapeutic efficacy of antiangiogenetic drugs by MRI[102]. An additional advantage 
of using nanosized assembled systems deals with the novel frontier of multimodal 
imaging. Liposomes appear excellent systems for designing probes containing 
imaging reporters that can be visualized with different imaging modalities. 
Most of the work in this field has been carried out by combining MRI and Optical 
imaging probes and it has been recently reviewed by Mulder et al. [103]. 
In the late 1980s, it was reported that paramagnetic low molecular weight Dy3+-
complexes can act as T2-susceptibility agents in MRI images when they are unequally 
distributed in vessels and in the surrounding tissues [104,105]. The effect can be further 
enhanced when the paramagnetic complexes are entrapped in vesicles such as 
liposomes[81,106]. The observed behavior is well accounted for in terms of the field 
gradients created by the compartment containing the paramagnetic ions that induce 
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the spin dephasing of the water protons diffusing in the outer region of the 
compartment. 
It is straightforward to note that any nanosized system containing paramagnetic metal 
ions would act as a T2-susceptibility agent. In this context, paramagnetic liposomes 
have a high potential owing to the high payload of paramagnetic complexes that can 
be either entrapped in their inner cavities or, upon suitable functionalization with 
lipophilic substituent, be incorporated in their membrane bilayer[107]. 
Figure 1.17 (on the left) compares the R2 values measured for an aqueous suspension 
of paramagnetic liposomes encapsulating DyHPDO3A and an aqueous solution 
containing the same total concentration of the paramagnetic metal ion. The transverse 
relaxation rate of the nanosized system is almost one order of magnitude higher at the 
magnetic field strength of 7 T. The R2-enhancement generated by the susceptibility 
effect is also evident in the in vitro MR image (Figure 1.17 on the right). 
 
 
 
Figure 1.17. Left: Effect of the liposome compartmentalization of a paramagnetic 
complex (Dy-HPDO3A) on the transverse rates at 7 T and 312 K. Right: In vitro 
RARE T2w MR image obtained at 7 T and 312 K. 
 
When normalized to the liposome concentration (in mmol/L), the transverse relaxivity 
ranges from 106 to 109 (mMLipo s)−1 (depending on the size and on the amount of 
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paramagnetic complex) at 7 T and 298 K. The high T2-relaxing efficiency displayed by 
these nanoprobes makes them very suitable for Molecular Imaging purposes. 
     
Figure 1.18. Size dependence of the transverse relaxivity (normalized to the 
liposome concentration) of POPC/Chol/DSPE-PEG2000 (55/40/5 in moles) liposomes 
encapsulated with a 200 mM solution of Gd-HPDO3A (14 T, 298 K). The line was 
only drawn for guiding eyes. 
 
The T2-susceptibility effect is also markedly dependent on the size of the vesicle 
entrapping the paramagnetic species as reported in Figure 1.18, where the transverse 
relaxivities of liposomes with different size, but filled up with the same concentration 
of Gd-HPDO3A, are compared. The reported R2-enhancement results from the 
increase of the number of paramagnetic centres encapsulated in the liposome cavity, 
which is proportional to vesicle volume. 
 
1.4.3 Blood pool agents 
 
Blood pool agents (BPA) or intravascular agents are significantly larger in size than 
ECF agents and have higher r1 relaxivities. Because of these characteristics, they offer 
many advantages in MRA relative to ECF agents. Their high molecular weight (>20 
kDa) prevents leakage into the interstitium and they remain in the intravascular 
system for a prolonged time compared with conventional ECF agents. The long 
intravascular half-life and the high r1 relaxivity allow imaging of the vasculature with 
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higher vessel-to-background signal ratio[108]. At the same time, their r2 relaxivity must 
be low enough to avoid excessive signal loss due to T2/T2 * relaxation. By selectively 
reducing the T1 of blood, high-quality angiograms can be obtained, including coronary 
artery imaging [109]. The concentration of the CA in the plasma remains stable over one 
hour, as its mainly renal elimination requires the previous degradation of the 
macromolecule. This extends the imaging window from about 1 min to about 1 h. This 
advantage of BPAs over ECF agents of longer image acquisition times allows higher 
resolution and/or better signal-to-noise ratio and leads to better-quality angiograms 
of several organs using respiratory or cardiac gating techniques. Vascular 
abnormalities, associated with certain tumors or atherosclerosis, can be detected and 
MR mammography is feasible [110]. Another advantage of using BPAs is that tissue 
blood volume and perfusion can be measured. Blood pool-enhanced MRA in the 
equilibrium phase (or steady state), as opposed to imaging during the initial arterial 
passage of the CA, offers the advantage of allowing the enhancement of both arteries 
and veins.  
The blood pool CAs can be divided into several classes, according to their mechanism 
of action: (a) the noncovalent binding of low molecular weight Gd3+ -based complexes 
to human serum albumin (HSA), which is the most abundant plasma protein (0.67 mM 
or 4.5% concentration in the blood plasma), prevents immediate leakage into the 
interstitial space; (b) systems based on polymers or liposomes, based on an increase in 
the size of the CA molecule, which slows down leakage through endothelial pores; 
and (c) systems based on particles, involving a change in the route of elimination. 
Other systems that are also being explored are small ECF Gd3+ complexes and Mn2+ -
labeled hydroxyapatite particles. 
Albumin-binding gadolinium complexes are the most successful approach so far. In 
this class, several complexes have been synthesized by attaching a hydrophobic moiety 
to a chelating agent, such as [Gd(DOTA-BOM3)] [111]. The most successful among these 
is the Gd3+ complex gadofosveset trisodium, previously known as MS-325 (Figure 
1.22), which became the first commercial agent in this class (Vasovist, Bayer Schering 
Pharma AG). It binds strongly and reversibly to serum albumin [112], leading to high 
relaxivity at clinical field strengths and much longer residence times in the blood 
compared with extracellular agents [113]. Several clinical studies have demonstrated its 
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efficacy in enhancing blood vessels, both in first-pass and in delayed steady-state MRA 
examinations. 
The second most valuable compound in this class is B-22956 or gadocoletic acid (Figure 
1.19; Bracco SpA) B-22956 is a Gd-DTPA derivative containing a cholic acid moiety 
with strong albumin binding [114]. This again leads to much longer residence times in 
the blood and a higher relaxivity compared with the unbound form of the CA. B-22956 
has been investigated for MR coronary artery imaging in clinical trials and to follow 
antiangiogenesis therapy [115], but is not yet commercially available. 
 
 
 
Figure 1.19. Structures of some HSA-binding and polymeric Gd3+ complexes, as 
potential or approved blood pool CAs for MRA (simplified structure for Gadomer 
17) (9,46,55). [Geraldes  et al 2009]. 
 
The albumin-binding Gd3+ complexes have a wide range of applications besides MRA, 
e.g. Dynamic Contrast Enhanced (DCE) MRI, breast MRI, perfusion MRI, lung 
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perfusion, etc. Malignant tumors often show an increased uptake and metabolism of 
plasma proteins, especially albumin. Macromolecular CAs are delivered to all tissues, 
but only accumulate in those with leaky vessels near tumor capillaries (tumor neo-
vessels). The outcome of tumor therapy can be followed using MRI tumor perfusion 
studies with Gd3+ -labeled albumin using the quantitative decrease in the MR signal 
of the malignant tissue after therapy. 
The large size of polymeric Gd3+ chelates is responsible for the slow (or absent) leakage 
of this class of CAs into the interstitial space through the normal endothelium of the 
vascular system, thus providing long imaging windows. Various polymeric agents 
(e.g. dextrans and polylysine derivatives) with molecular weights in the 15–5000 kDa 
range were evaluated, but did not pass beyond the preclinical stage [116]. Their large 
size leads to slow rotational dynamics and increased relaxivity at clinical field 
strengths. Excretion of Gd3+ -based macromolecular CAs is related to their size. Since 
the molecular weight of these large molecules exceeds 40 kDa, glomerular filtration 
decreases, which could lead to problems with their excretion, even if they are excellent 
MRA agents. 
An example of this class of CAs undergoing clinical trials is Gadomer 17 (Bayer 
Schering Pharma AG), which carries 24 Gd3+ ions [117]. Because of their size (molecular 
weight 35 kDa), Gadomer 17 molecules are large enough to show much slower leakage 
through normally functioning endothelium than extracellular agents, but are still 
small enough to be eliminated via the kidneys. Imaging studies in animals have 
resulted in excellent angiograms, allowing quantitative perfusion studies of the 
myocardium. It has been also successfully employed to demonstrate differences in 
endothelial permeability between tumors and healthy tissue [118]. 
(Gd-DTPA)45-HSA is another example of this type of CA. Aime et al. [119]]have studied 
the frequency and temperature dependence of proton and oxygen-17 relaxivities of 
this CA. The observed behavior is typical of systems whose relaxivity is limited by a 
long exchange lifetime of the coordinated water molecule [120]. 
Sieving et al. (50) have synthesized a poly-(L-lysine) containing 60–90 chelating groups 
(DTPA or DOTA). Complexed with Gd3+ ions, the paramagnetic chains were 
conjugated to HSA. The relatively small relaxation enhancement shown by Gd3+ 
complexes when bound to polylysine is accounted for by the high internal mobility of 
51 
 
the paramagnetic moiety. An analogous result has been observed using the squaric 
acid unit as a linker between the macromolecule and the Gd chelates [121]. Another 
agent of this class undergoing clinical trials is P-792 (Gadomelitol, Vistarem1, 
Guerbet), a hydrophilic high molecular weight derivative of Gd-DOTA. This is a rapid 
clearance blood pool agent, owing to its limited diffusion across the normal 
endothelium, with high proton relaxivities r1 and r2 in the current range of clinical 
imaging magnetic fields [122]. 
The polymeric agent (Gd-DTPA)n-polylysine, under development (PLLGd-DTPA, 
preclin., Bayer Schering Pharma AG), shows advantages in MRA, in perfusion studies 
of the myocardium and lung perfusion, and in the differential diagnosis of tumors.  
However, none of the polymeric Gd3+ complex CAs are yet commercially available. 
The loading of micelles and liposomes with amphiphilic polychelate polymers has 
been reported also and different paramagnetic agents have been encapsulated into the 
liposomes [123]. However, these studies did not lead to any agent which passed the 
preclinical status. 
 
 
1.4.4.2 Organ-specific agents 
 
The diagnosis of hepatic lesions continues to be a problem even though many 
diagnostic methods are available. Despite the high contrast resolution of T2-weighted 
MRI techniques, a number of pathologies are difficult to detect or differentiate without 
CAs. ECF agents (e.g. Magnevist) rapidly distribute in the vascular and interstitial 
space, but do not pass plasma membranes and thus have negligible hepatocellular 
uptake and biliary excretion. Targeting the hepatocytes or entrapping substances in 
macrophages of the reticuloendothelial system (RES) are effective approaches for liver-
specific agents since both pathways have a high capacity for handling relatively 
unspecific materials. 
Several compounds with different magnetic properties are currently in clinical use, 
trials, or in preclinical development. They are divided in two main categories: (a) 
agents targeting hepatocytes—small paramagnetic complexes; and (b) agents targeting 
the RES— magnetic particles and magnetic liposomes.  
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Figure 1.20. Chemical structures of the water-soluble paramagnetic chelates with 
hepatobiliary uptake in clinical use. 
 
The small water-soluble paramagnetic chelates with hepatobiliary uptake in clinical 
use (see ligand structures in Figure 1.20) are the Gd-DTPA derivatives [Gd(EOB-
DTPA)(H2O)]Na2 [gadoxetic acid disodium, PrimovistTM (formerly Eovist 1 ), Bayer 
Schering Pharma AG] and [Gd(BOPTA)(H2O)](MEG)2 (gadobenate dimeglumine, 
MultiHance, Bracco SpA) and the Mn2+ chelate [Mn(DPDP)]HNa3 (mangafodipir 
trisodium, Teslascan, GE Healthcare). 
The extracellular Gd-DTPA-type derivatives exhibit the most useful characteristics. 
Both have one lipophilic residue attached to the DTPA backbone that targets the agent 
to an organic anion transporter in the sinusoidal plasma membrane of the hepatocyte. 
The uptake by hepatocytes decreases T1 and increases the signal intensity of normal 
liver parenchyma, giving a positive contrast relative to other tissues. These CAs 
display a very pronounced hydrophilic character and relatively low plasma protein 
binding, despite the presence of the lipophilic moiety, which gives them an acute 
intravenous tolerance as good as that of Magnevist. [Gd(EOB-DTPA)(H2O)]2- , with the 
ethoxybenzyl group [124], is completely eliminated from the body, with 50% 
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hepatobiliary and 50% renal excretion. After entering the intracellular space of the 
hepatocyte, it is sequestered in the bile. The excretion through the bile and feces causes 
the bile ducts and the gall bladder to display a very short T1, which makes contrast-
enhanced cholangiography possible. Shortly after administration, the compound 
distributes in the vascular system in the same way as Magnevist1 , allowing the blood 
vessels to be seen in dynamic imaging studies. While the Gd3+ concentration and the 
signal intensity in blood decrease, the signal of the liver parenchyma increases, 
reaching maximum brightness 30–60 min after injection [125]. [Gd(BOPTA)(H2O)]2-  has 
a benzyloxy lipophilic moiety bound to the DTPA backbone at a different position, 
providing similar properties to the above described chelate [126]. In addition to the liver, 
it can be used for MRI of brain and spine. Both Gd3+ agents significantly bind to HSA, 
although with at least one order of magnitude lower affinities than for HSA-binding 
blood pool agents [127]. Because of the resulting increased relaxivity and half-life in 
blood, they can be also used in MRA applications [128]. 
[Mn(DPDP)]4- [129] is the first Mn2+ complex to be used as contrast agent in clinical trials 
[130]. The ion is a powerful T1 relaxation agent because of its five unpaired electrons. 
This CA, which demonstrates both biliary and renal excretion, has been shown to be a 
positive and very effective liver enhancer in T1-weighted images. Pharmacokinetic 
studies have shown that, shortly after injection, some Mn2+ is released in the plasma 
and the paramagnetic ion accumulates in the liver and other tissues like pancreas and 
cardiac muscle. Free Mn2+ ions are known to accumulate in hepatocytes, although the 
chemical similarity of DPDP to vitamin B6 may also contribute to hepatocyte uptake. 
Since Mn2+ is a powerful relaxation enhancer, a very small amount (5 mmol/kg) is 
sufficient to significantly enhance the contrast between the healthy liver parenchyma 
and focal liver lesions. 
 
 
Gadofluorine 8 (Bayer Schering Pharma AG) is a lipophilic but water-soluble 
gadolinium complex that accumulates in normal lymph nodes, resulting in a 
pronounced increase in their signal intensity, but not in malignant (metastatic) nodes, 
thus allowing their differential diagnosis [131]. 
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1.4.4  Targeting and cell labelling  
 
Targeted CAs are probes able to recognize specific molecular sites (e.g. cell-specific 
receptors or transport proteins) at the cellular membrane and to accumulate at those 
sites, in most cases by becoming trapped in the intracellular space. The development 
of approaches able to recognize and image a specific molecular marker of a given 
pathological process or state (molecular imaging), such as inflammation, 
atherosclerosis, angiogenesis, apoptosis and tumors, makes the task of diagnosis and 
therapy much easier [132]. Thus, the development of high affinity ligands as targeting 
vectors and their conjugation to Gd3+ chelates as reporter groups (Figure 1.21, A) is one 
of the requirements for efficient molecular probes. 
 
Figure 1.21. General structure of a targeted CA for cell labeling: (A) with a single 
reporter group; (B) with a carrier of many reporter groups. 
 
However, the main problem of this approach using Gd3+ -based contrast agents is 
MRI’s low sensitivity, so that to reach 50% of contrast enhancement it is necessary to 
have a local concentration of CA of the order of 0.5 mM. It is possible to increase the 
payload of reporter groups delivered at the target site by using many reporters bound 
to a single carrier (Figure 1.24, B). However, this combined with the very low 
concentration of receptors in the cell membrane (10-9 –10-13 mol/g of tissue) makes it 
difficult to obtain an image with good contrast. Also, the saturation of all available 
receptors would interfere with the normal metabolic equilibrium, leading possibly to 
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cell death [133]. The minimum detectable concentration of a CA depends on its 
relaxivity. While for [Gd(HPDO3A)] (r1 = 3.7 mM-1 s-1 at 90 MHz) this value is too high 
(5 × 10-7 mol/g or 100 mM), for a sixth-generation dendrimer conjugate substituted 
with 170 Gd-DTPA chelates (r1 = 5800 mM-1 s-1 per dendrimer) it has a manageable 
value (1.9 × 10-10 mol/g). The main targeting strategies are cell surface or receptor 
targeting. In the first approach, specific epitopes easily available at the cell surface are 
targeted. This has been used together with the pretargeting approach to facilitate the 
detection and imaging of tumor cells (some of which are known to have abnormally 
high negative charges on their cell surface). This approach consists of two steps, first  
a positively charged polypeptide, such as polyarginine,  interacts on tumor cell 
surface,  then, a negatively charged CA [Gd(DO3A)-R, where R = CH2–C( =O) N(CH2–
PO32-)2] is added in order to stick on positively charged polypeptide [134]. The use of 
low-molecular-weight targeting CAs, able to accumulate quickly at specific cell surface 
sites, has several advantages with respect to macromolecular agents. One example is 
the use ofmodified Gd3+ chelates able to recognise the abnormal glycosilation of tumor 
cell surfaces, which have much higher content of sialic acid residues (>109 /cell) than 
normal cells (>106 /cell) [135]. 
Other relevant examples of cell surface targeting result from the well-known 
nonspecific binding of porphyrins to the interstitial space of tumors, e.g. Dy-TPPS 
(TPPS = tetraphenylporphyrin sulfonate). One expanded porphyrin (texaphyrin) 
complex, [Gd(Tex)]2+  (PCI-120), selectively accumulates at tumor sites, giving 
prolonged enhancement of MRI images and the possibility of being used as a radiation 
sensitizer for brain cancer [136]. Gadophyrin-2 [mesoporphyrin-(GdDTPA)2] (Bayer 
Schering Pharma AG) targets the necrotic part of tumors, possibly through binding to 
cell proteins released upon cell death by necrosis. This specific accumulation of 
necrosis-avid CAs (NACAs) provides a prolonged enhancement of necrotic tissue, 
especially of myocardial infarcts [136]. 
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The targeting of cell surface receptors can be pursued using labeled antibodies or low-
molecular-weight targeting complexes. 
 
Figure 1.22. Schematic representation of targeting of the endothelial αVβ3  
angiogenesis marker [138]. 
 
In the first approach, due to the slow diffusion of the antibodies, the most accessible 
targets are those present on the endothelial vessels. A typical example is the targeting 
of the endothelial integrin receptor αVβ3, a specific angiogenesis marker whose 
concentration correlates with the tumor grade. A Gd3+-containing polymerized 
liposome was used as an example of an imaging probe containing many reporter 
groups per carrier. The pretargeting approach was used, where the target  was bound 
first to a biotinylated monoclonal antibody against αVβ3, which is well recognized by 
an avidin moiety present on the liposome surface carrying the Gd3+ chelate reporter 
groups (Figure 1.22) [138]. 
The same αVβ3 target has been addressed with lipidic nanoparticles containing Gd3+ 
chelates [139]. Although the possibility of extensive substitution of some antibodies 
without loss of immunoreactivity has been demonstrated when they are labeled with 
liposomes, dendrimers or polymeric chelates, and nanoparticles, the large molecular 
size and, therefore, the slow delivery of these systems limit the technique. 
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A more efficient way to accumulate CAs at the target site is by cell internalization 
processes, which, to be successful, require that the concentration of the agent inside 
the cell is higher than at the cell surface. These internalization processes may occur via 
phagocytosis and pinocytosis (or fluid phase endocytosis) mechanisms, which do not 
require a cell receptor, or receptor mediated endocytosis. Phagocytosis, the process of 
internalization of particles by cells endowed with phagocytic activity, has been used 
with Gd-DTPA bis-stearylamide derivatives forming insoluble Gd3+ -containing 
particles that, after internalization, are biodegraded and become soluble and trapped 
inside the cell [140]. Gd-HPDO3A has been used for labeling stem cells via the 
pinocytosis mechanism, where the stem cells are incubated in a culture medium 
containing Gd-HPDO3A in the mM concentration range (10–50 mM) [141]. However, 
these processes are often very slow and only apply efficiently to undifferentiated, 
dividing cells. One example of cell internalization by receptor-mediated endocytosis 
is the entrapment of several units of a CA inside the inner spherical cavity of 
apoferritin, which after intravenous administration is quickly cleared up by specific 
receptors on hepatocytes [142]. However, except in the case of internalization by 
electroporation, where it is delivered to the cytoplasm, the CA is entrapped in the cell 
endosomic compartment, seriously limiting its relaxivity [143]. 
Other cell internalization mechanisms have used membrane transporters and 
transmembrane carrier peptides. These latter have proven useful for the 
internalization of a number of substrates like proteins, oligonucleotides and plasmid 
DNA. For instance, translocating signal (MTS) peptides, such as the TAT peptide, 
made up of a sequence of 10 amino acids from the HIV-1 TAT protein, conjugated to 
iron oxide nanoparticles or to Gd-DTPA were efficiently internalized [144]. Another 
interesting development was the synthesis of a bimodal (optical and MRI) imaging 
probe consisting of a Gd3+ /Eu3+ -DOTA complex, a PNA (peptide nucleic acid) 
sequence and a transmembrane carrier peptide. Although the system enters any type 
of cell, it accumulates only in tumor cells because of the specific binding of the PNA 
moiety to the c-myc mRNA whose production is upregulated in those cells. This 
bioshuttle conjugate—transporting the imaging probe into the cytoplasm and then 
into the nucleus—thus works as a nuclear localization sequence, and has proven to 
accumulate in the nucleus of DU-145 prostate cancer cells [145].        
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1.5 Aim of the work    
 
 
In this introductive chapter, some of the most interesting and applied ways to prepare 
highly-efficient MRI contrast agents were discussed. The main parameters influencing 
the relaxivity of a MRI contrast agent were defined and explained, in order to 
understand which kind of structural requirements a paramagnetic complex must 
satisfy to optimize its output in terms of r1p, like the number of coordinated water 
molecules q, the reorientational correlation time τR and the residence lifetime of the 
coordinated water molecules τM. A wide overview of systems studying the modulation 
of these parameters was proposed, with particular attention to those systems that 
approach the optimization a MRI contrast agent in a similar manner to that reported 
in the following chapters of this PhD thesis.   
As first goal of our work, we will identify, synthesize and characterize an organic 
ligand to be used as a building block for the development of high-efficiency MRI 
contrast agents. Thus, the structural, thermodynamic and kinetic properties of the  
dimeric AAZTA-like complex Gd2L will be described in Chapter 2. 
Once detected this well-performing paramagnetic complex, we will use it as a starting 
point to develop high-relaxivity systems using different approaches. 
Focusing our attention on the dependence of relaxivity as a function of τR, the dimeric 
ligand L will be functionalized with a hydrophobic group able to form inclusion 
compounds through non-covalent interactions between the Gd-complex and 
macromolecules such as β-CDs and poly-β-CDs, or proteins like HSA (Chapter 3). 
Furthermore, the covalent binding of this dimeric Gd-complex to a rhodamine 
functionalized dextran will yield a multimodal imaging probe for in vivo 
neuroanatomical analysis of monosynaptic connections. This work was carried out in 
collaboration with the Max Planck Institute for Biological Cybernetics, Tubingen, 
Germany. It will be shown that the derivative containing the dimeric AAZTA moiety 
gives higher MR contrast enhancement with respect to a mono-AAZTA functionalized 
dextran (Chapter 4). 
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Finally, we will synthesize and characterize AAZTA-like mono- and multimeric 
paramagnetic amphiphilic complexes, bearing lipophilic moieties such as single 
and/or double aliphatic chains. The development of high-relaxivity lipid 
nanoparticles including these q = 2 paramagnetic systems will be the target of this 
Chapter. The aim will be to increase the local rigidity of the amphiphilic complexes by 
using multimeric complexes and double aliphatic chains to obtain lipidic nanoparticles 
with optimized efficiency (Chapter 5).  
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2. AAZTA-Dimer, a novel building block for 
high relaxivity systems 
 
 
 
In the introduction chapter some of the most known and common ways to obtain high-
efficiency contrast agents are reported.  
Often, to obtain a suitable probe, a functionalization of the paramagnetic complex is 
required. Consequently, in first istance is necessary to design a well-performing 
paramagnetic core as a substrate for the functionalization. In this PhD project a dimeric 
AAZTA-like complex, L (Scheme 2.1), was synthesised and characterized, as a 
promising building block for the preparation of high-relaxivity systems.   
AAZTA and its derivatives have been proposed for diagnostic and therapeutic 
applications for several reasons: they are relatively easy to synthesise [1] and form 
thermodynamically stable and kinetically inert complexes with divalent and trivalent 
metal ions.[2,3] In our earlier work, we found that Gd3+-complexes of the multimeric 
AAZTA ligands shows excellent relaxation enhancement of the solvent water protons, 
which can be attributed to the slow reorientational correlation time of the multimeric 
complexes and the fast exchange between the bulk and two water molecules directly 
coordinated to the Gd3+ ion.[4]   
The metal complexes used in the medical diagnosis and therapy must have high 
thermodynamic stability and kinetic inertness since the free metal ions and ligands are 
toxic. The detailed equilibrium and kinetic characterization of Gd2L was performed in 
order to predict the distribution and the dissociation rate of the Gd3+-complex near 
physiological conditions. 
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2.1 Synthetic procedure  
 
The synthesis of the dimeric lignad was carried out starting from 5-nitro-isophthalic 
acid which was transformed into a bis-acyl azide passing through the acyl chloride . 
and then performing a substitution with sodium azide in a mixture of NaOH (1.0 mol 
L-1) and CH2Cl2 (Scheme 2.1). The acyl azide was then converted into the isocyanate 
through Curtius rearrangement refluxing in toluene for 3h. 
 
Scheme 2.1: Synthetic procedure to obtain L. Reagents and conditions: i: SOCl2, 
reflux, 18 h; ii: NaN3, NaOH 1 M/CH2Cl2, rt, 1 h; iii: Toluene, reflux, 3 h; iv: CH2Cl2, 
rt, overnight; v: TFA/CH2Cl2, rt, overnight. 
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Scheme 2.2: Complexation of L with GdCl3. 
 
The 5-nitro isophthaloyl diisocyanate was then reacted with two equivalents of 
AAZTA- OH, whose synthesis is reported in literature[gugliotta tei 2009], to obtain the 
dimeric ligand (II) after column chromatographic purification.  After purification the 
final dimeric lingad L was obtained by deprotection of the t-Bu esters with 
trifluoroacetic acid in CH2Cl2 1:1 v/v. 
Eventually, the dimeric  Gd3+ complex Gd2L was obtained trough relaxometric 
titration with GdCl3. Once reached the equivalence point, and some free Gd3+ is in 
solution, the complex generates some kind of aggregates that precipitate. To 
resolubilize the complex a small amount of solid ligand was added, being sure this 
way that all the Gd3+ in solution is complexed. 
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2.2 Thermodynamic study 
 
Figure 2.1. pH-potentiometric titration curve of L in the absence (1) and presence of 
Gd3+ and Cu2+ ions. ([L]=2.0 mM, [Gd3+]=2.0 mM (2), [Gd3+]=4.0 mM (3), [Cu2+]=2.0 
mM (4) and [Cu2+]=4.0 mM (5), [HCl]=10 mM, 0.1 M KCl, 25C).  
In the frame of the Hungarian – Italian Intergovernmental Science & Technology 
Cooperation Program, a period was spent at the Department of Inorganic and 
Analytical Chemistry, University of Debrecen were the protonation constants of the 
dimeric AAZTA ligand L were determined and the complexation equilibria of L with 
Gd3+ and Cu2+ ions investigated.  
The detailed equilibrium and kinetic characterization of Gd2L was performed in order 
to predict the distribution and the dissociation rate of the Gd3+-complex near 
physiological conditions. In particular, the protonation constants of L, the stability and 
protonation constants of the Gd3+ and Cu2+-complexes formed with L were determined 
by pH-potentiometric titrations. The metal-to-ligand concentration ratios used as 
conditions for the titrations were 1:1 and 2:1 (the concentration of the ligand was 
generally 0.002 M). For the pH measurements and titration, a Metrohm 785 DMP Titrino 
workstation and a Metrohm-6.0233.100 combined electrode were used. Equilibrium 
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measurements were carried out at constant ionic strength (0.1M KCl) in 6 ml samples 
at 25 C. The titrations were performed  in the pH range 1.7-11.7 stirring the solutions 
under N2 atmosphere. The protonation and stability constants were calculated with 
the program PSEQUAD. The pH-potentiometric titration curve of the L, the Gd3+-L 
and Cu2+-L systems are shown in Figure 2.1. 
  
 
Table 2.1: The protonation constants calculated for L. 
 
The comparison of the related logK values( Table 2.1), that are a quantitative measure 
of the strength of an acid in solution, indicates that the protonation behavior of L and 
AAZTA is similar due to the presence of identical protonation sites. However, the logK 
values of the two AAZTA units of L are slightly different (by 0.5 logK unit) indicating 
an interaction between the two independent AAZTA units. By taking into account the 
protonation constants of L, the stability and protonation constants of the Gd3+ and Cu2+ 
 L AAZTA 
logK1H 10.36 ± 0.01 11.23 
logK2H 9.96 ± 0.01 6.52 
logK3H 6.06 ± 0.01 3.78 
logK4H 5.49 ± 0.02 2.24 
logK5H 4.20 ± 0.02 1.56 
logK6H 3.88 ± 0.02 - 
logK7H 3.12 ± 0.03 - 
logK8H 2.90 ± 0.03 - 
logK9H 2.04 ± 0.02 - 
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complexes were calculated from the pH-potentiometric titration curves obtained at 1:1 
and 2:1 metal-to-ligand concentration ratios. 
 
Table 2.2: The protonation constants calculated for GdL and Gd2L. 
The lower stability constant of the dinuclear Gd2L complex with respect to GdAAZTA 
is probably caused by the lower protonation constants of the second AAZTA unit. On 
the other hand, because of the high stability of the CuL and Cu2L complexes, the 
logKCuL and logKCu2L values could not be calculated from the pH-potentiometric data 
(the complex formation was completed at pH=2.0). However, the lower limit of the 
logKCuL and logKCu2L values could be evaluated by the simultaneous fitting of the VmL 
– pH data pairs obtained at 1:1 and 2:1 metal-to-ligand concentration ratios. The 
estimated stability constants of CuL and Cu2L are: logKCuL ~ logKCu2L > 21. The 
protonation constants of the CuL and Cu2L complexes calculated from the pH-
potentiometric titration curves are in line with expected values for similar systems. 
The protonation constants of the mononuclear GdL and CuL complexes and the 
logK2H, logK4H, logK6H and logK8H values of the free L ligand are similar confirming 
the formation of the mononuclear complexes and a free AAZTA unit in the systems of 
1:1 metal-to-ligand concentration ratio. However, the pH-potentiometric method is not 
 L AAZTA 
logKGdL 19.80 ± 0.02 20.24 
logKGdHL 9.65 ± 0.02 1.89 
logKGdH2L 5.65 ± 0.02 - 
logKGdH3L 3.96 ± 0.02 - 
logKGdH4L 3.01 ± 0.02 - 
logKGdH5L 2.05 ± 0.02 - 
logKGd2L 18.60 ± 0.03 - 
logKGd2LH 2.12 ± 0.03 - 
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able to discriminate if the 1:1 complex formation between L and Gd3+ or Cu2+ ions takes 
place via the mononuclear GdL and CuL complexes with one free AAZTA unit or via 
the dimeric Gd2L and Cu2L complexes leaving half equivalents of L free.  
 
2.3 Kinetic study 
 
In collaboration with the Department of Inorganic and Analytical Chemistry of the 
University of Debrecen, a kinetic study of Gd2L was also performed following the 
transmetallation reaction of the Gd3+ complex in presence of Cu2+.   
To avoid the typical precipitation that occurs to this system when in presence of free 
Gd3+, the transmetallation reactions of the Gd2L complex with Cu2+ were studied in a 
citrate (Cit) solution. Citrate is contained in human serum and is expected to 
coordinate any Gd3+ ion released from the CA giving  Gd3+-citrate complexes. The 
transmetallation/exchange reactions studied can be described by the Equations (1) 
and (2): 
 
                                 Gd2L  +   2Cu(Cit)H-1        2Gd(Cit)  +  Cu2L  +  2OH-                               (1) 
 
Gd2L  +   2Cu(Cit)H-1        2Gd(Cit)H-1  +  Cu2L                              (2) 
 
The stability constants of the Cu(AAZTA)2- and (Cu2L)4- complexes are significantly 
higher than those of the Gd(AAZTA) and Gd2L, so the reactions (1 and 2) take place 
quantitatively. 
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The rates of the reactions (1 and 2) were studied by spectrophotometry (Figure 2.2) by 
recording the absorption spectra for the reactions between Gd2L and Cu(Cit)H-1 as a 
function of time. The spectra of Cu(Cit)H-1 and Cu2L differ considerably in the 
wavelength range 270 – 320 nm and so the progress of the reactions (1 and 2) was 
monitored at 290 nm with a Cary 1E spectrophotometer at 25C.  
 
Figure 2.2. The absorption spectra of the Gd2L – Cu(Citrate) reacting system 
([Gd2L1]=2.0×10-4 M, [Cu(Cit)H-1]=0.01 M, pH=5.5, l=0.1 cm, 0.1 M KCl, 25C) 
 
The absorbance values vs time trace of Gd2L / Cu(Cit)H-1 reacting system (Figure 2.3) 
can be fitted with the mono-exponential equation (At=Ae + (A0 - Ae) × e-kd×t, where kd, 
A0, Ae and At are the pseudo-first-order rate constant, the absorbance values at the start, 
at equilibrium and at the time t of the reaction, respectively), which indicates that the 
exchange reactions of both Gd(AAZTA) units of Gd2L with Cu(Cit)H-1 are similar.  
The rates of the exchange reactions between the complexes Gd2L and Cu2+-citrate were 
studied in the pH range 5.5–7.5 and the kd values could be obtained by fitting the data 
reported in Figure 2.4 and 2.5. 
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Figure 2.3. Absorbance values of the Gd2L / Cu(Cit)H-1 reaction system at 290 nm 
([Gd2L]=210-4 M, [Cu(Cit)]= 1.010-3  M, [MES]=0.01 M, pH=5.55, 0.1 M KCl, l=0.2 
cm, 25C). 
 
Figure 2.4. Rate constants (kd) for the transmetallation reactions between Gd2L and 
Cu(Cit)H-1 ([Gd2L]=2×10-4 M, [Cu(Cit)H-1]=4×10-3 M (), 6×10-3 M (■), 8×10-3 M (▲) 
and 1×10-2 M (●), 0.1 M KCl, 25C). 
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Figure 2.5. Rate constants (kd) for the transmetallation reactions between Gd2L and 
Cu(Cit)H-1. ([Gd2 L]=2×10-4 M, [Cu(Cit)H-1]=4×10-3 M (), 6×10-3 M (■), 8×10-3 M (▲) 
and 1×10-2 M (●), 0.1 M KCl, 25C). 
 
 
The kinetic data presented in Figures 2.4 and 2.5 indicate that the rates of the exchange 
reactions are not [Cu(Cit)H-1] dependent and increase linearly with the increase of the 
H+ concentration. These findings show that under such conditions the reactions occur 
through the dissociation of complexes. The rate determining step is probably the 
spontaneous and proton assisted dissociation of the Gd2L complex which is followed 
by the fast reaction between the free L ligand and Cu2+ with the formation of Cu2L. So, 
the rate of the exchange reactions is directly proportional to the concentration of the 
Gd3+ complex and can be expressed by Equation (3): 
 
(3) 
 
where [GdL]t and kd are the total concentration of the Gd3+ complex and the pseudo-
first-order rate constant, respectively. 
The kd values presented in Figure 2.5 can be given as follows: 
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   kd  =  k0   +    k1[H+]                                                       (4) 
 
where k0 and k1 are the rate constants characterizing the spontaneous and proton 
assisted dissociation, respectively. The k0 and k1 values were calculated from the kd data 
presented in Figure 2.5, but only k1 value is reported in Table 2.3, because a significant 
evaluation of k0 was not possible. Unlikely, Gd2L shows a lower kinetic intertness, if 
compare with the monomeric GdAAZTA or the q = 1 complex GdDTPA. Anyway its 
stability is higher than amidic systems as Gd(DTPA-BMA) is. 
 
 Gd2L Gd(AAZTA)a Gd(DTPA)b Gd(DTPA-
BMA)c 
k1 (M-1s-1) 5.03 ± 0.03 1.12 0.58  12.7  
 
2.4  1H relaxometric properties  
The 1H NMR relaxometric characterization of Gd2L was also carried out in order to 
obtain the relaxometric parameters and to confirm the good performance expected for 
such a probe.  
The obtained data confirms, first of all, a good outcome in terms of r1p of the dimeric 
complex, with a value of 14.1 mM-1 s-1, consistent with values reported in literature for 
similar dimeric complexes[diaazta tei].  
In Figure 2.6 the relaxometric titration of L with GdCl3 is reported. The slope of the 
obtained line is 14.6, very close with the r1p value confirmed through magnetic 
susceptibility measurement of 14.1 mM-1 s-1. 
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Figure 2.6. Complexometric titration of L with GdCl3, followed by 1H relaxometric 
measurements at 298 K and 20 MHz. 
To get more insight, the1 H nuclear magnetic relaxation dispersion (NMRD) profiles 
of Gd2L were recorded in aqueous solution at pH 7 and at 298 K (Figure 2.7). 
The relaxivity per gadolinium atom is comparable to or even higher than that of other 
Gd3+ dimers [25–27], and is almost unchanged over a large range of magnetic fields, as 
expected, thus being interesting for applications in high-field MRI studies. 
 
Figure 2.7. 1H NMRD profile of Gd2L, at pH 7, 298 K and [Gd]=1.07 mM. 
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Figure 2.8. r1p as a temperature function, measured at pH 7, 20 MHz and [Gd]= 3.9 
mM. 
The AAZTA cage is characterized by a fast water exchange rate- regime[ref]. In order to 
confirm that this feature is maintained also in the dimeric Gd2L system a temperature-
dependence measurement of r1p was performed. 
As reported in Figure 2.8, the r1p behave as a lorentzian function of temperature, as 
usual for fast water exchange regime systems. 
 
2.5 Conclusions 
 
The dimeric AAZTA-like complex Gd2L was synthesized and purified in good yelds. 
The thermodynamic and kinetic properties of the paramagnetic complex were 
investigated in order to determine if the complex has enough stability and kinetic 
inertness to allow a safe in vivo administration.  
A 1H relaxometric investigation was also performed, showing how Gd2L seems to be 
a promising starting point for the development of high-relaxivity systems. His dimeric 
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and quite-rigid structure results in a good outcome in terms of r1p (14.07 mM-1 s.1 at 
25°C and 20 MHz), maintained also at higher magnetic fields. 
Eventually, the nitro-group on L aromatic ring allows an easy functionalization of the 
ligand, in order to achieve any structural feature required for a wide range of covalent 
and non-covalent interactions, as reported in the following chapters of this thesis. 
 
2.6 Experimental part 
 
1-Nitro-3,5-benzenedicarbonyldiazide.  
A solution of 1-nitroisophthaloyl dichloride (2.890 g; 11.7 mmol) in dry CH2Cl (20 mL) 
was added drop wise in 2 min to an ice-bath cooled mixture of NaN3 (7.6 g; 117 mmol) 
in  and CH2Cl2 (30 mL), under vigorous magnetic stirring. The ice-bath was removed 
after 5 min and the mixture was stirred for overnight at room temperature. The 
mixture was washed with water (3 x 20 mL); then, the organic phase was collected, 
dried over NaSO4, filtered and evaporated to yield a white solid (2.615 g, 85%). 
1H-NMR: (CDCl3) 400 MHz δ = 9.0 (d, 2H, J = 1.8 Hz), 8.9 (t, 1H, J =1.8 Hz). 13C-NMR: 
(CDCl3) 100 MHz δ = 169.7 (CO), 148.8 (C), 135.1 (CH), 133.3 (2C), 128.8 (2CH). 
 
 
II 
1-Nitro-3,5-benzenedicarbonyldiazide (303 mg; 1.15 mmol) was heated to reflux for 3 
h in dry toluene, under N2. After cooling to room temperature, a solution of AAZTA-
OH (1.385 g; 2.30 mmol) in dry CH2Cl2 (3 mL) was added under N2 atmosphere. The 
reaction mixture was stirred overnight at rt, and then evaporated in vacuo. The crude 
product was purified on a silica gel chromatography column (petroleum ether/ethyl 
acetate 70/30) yielding pure II as a pale yellow solid (1.478 g, 91%).  
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TLC (silica gel 60 F254, petroleum ether/EtOAc 8 : 2, detection: UV 254 nm): Rf 0.35. 
1H-NMR (CDCl3) 500 MHz δ = 8.03 (s, 2H, CH), 7.93 (bs, 2H, NH), 7.79 (s, 1H, CH), 
4.23 (s, 4H, CH2OCO), 3.68 (s, 8H, CH2CO), 3.25 (s, 4H, CH2CO), 3.24 (s, 4H, CH2CO), 
3.08 (d, 4H, J = 14.3 Hz, CH2C), 2.78 (d, 4H, J = 14.3 Hz, CH2C), 2.80–2.63 (m, 8H, 
CH2CH2), 1.42 (s, 36H, CH3), 1.41 (s, 36H, CH3). 13C-NMR (CDCl3) 125 MHz δ = 172.8, 
170.7 (CO), 153.2 (NHCOO), 149.3 (C), 140.0 (2C), 113.0 (CH), 107.6 (2CH), 81.0, 80.8 
(CCH3), 68.1 (CH2OCO), 63.3 (C), 62.3, 62.1 (CH2CO), 59.0, 51.7 (CH2cyclo), 28.3, 28.2 
(CH3). ESI-MS (m/z): 1408.78 (M + H+ ); calc for C68H114N9O22: 1408.81.  
 
L 
TFA (3 mL) was added dropwise to a solution of II (350 mg, 0.248 mmol) in CH2Cl2 (3 
mL). The mixture was stirred at room temperature overnight and then evaporated in 
vacuo. The solid residue was washed twice with Et2O (10 mL) and isolated by 
centrifugation. Then it was dried in vacuo, resulting in L as its trifluoroacetate salt.  
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3. AAZTA-dimer functionalization with an 
adamantyl moiety and  formation of 
supramolecular inclusion compounds 
 
As detailed in the introduction chapter, according to the established theory of 
paramagnetic relaxation, large longitudinal relaxivity (r1) enhancements can be mainly 
pursued by: 
(1) increasing the hydration number (q),  
(2) optimizing the mean residence lifetime (τM) of the coordinated water molecule(s), 
(3) lengthening the rotational molecular correlation time (τR) [1–3].  
It was recognized very early that the rotational dynamics is the main factor controlling 
the efficiency of the low molecular weight Gd3+ chelates. The reversible formation of 
adducts with human serum albumin (HSA) has been one of the major routes to achieve 
high relaxation enhancement for Gd3+ complexes as a result of the reduced rotational 
tumbling rate (1/ τR) of the macromolecular adduct [4, 5].  
Slow-tumbling systems with large τR can be obtained through different approaches: 
(i) contrast agents covalently bound to dendrimers, polymers, proteins, or virus 
capsids [1, 6–9];  
(ii) aggregated systems, such as micelles or liposomes [1, 10–12];  
(iii) suitably functionalized probes that can interact noncovalently with proteins or 
other types of macromolecules [1, 4, 5].  
The large array of molecular recognition pathways provided by supramolecular 
chemistry allows one to exploit several systems for attaining large aggregates with 
high binding constants. For example, HSA has been largely used for the formation of 
adducts with Gd3+ chelates bearing hydrophobic functionalities, taking advantage not 
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only of the relaxivity enhancement generated by the noncovalent interaction, but also 
of the lengthening of the lifetime of the contrast agent in the bloodstream [1, 4, 5, 13, 14]. 
The latter issue plays a relevant role in the development of magnetic resonance 
angiography probes. 
In the case of Gd3+ -based contrast agents, a well established and attractive approach 
to attain large τR values relies on the reversible formation of adducts between suitably 
functionalized complexes and macromolecular substrates [4, 5]. An optimized Gd3+ 
probe bearing a hydrophobic moiety, able to form supramolecular adducts with a 
given substrate, would be a promising system to achieve high relaxivities. For this 
purpose we chose GdAAZTA [15, 16] as a complex that combines high thermodynamic 
and kinetic stabilities with the presence of two water molecules in the inner 
coordination sphere (q = 2) in fast exchange with the bulk (see Chapter 2). Moreover, 
the use of the recently reported [17] dimeric bifunctional chelating agent bearing two 
AAZTA units and an isothiocyanate group for conjugation allows further optimization 
owing to the higher relaxivity (per Gd atom) of the dimeric complex with respect to 
the monomer as a consequence of its higher molecular weight, which translates into 
slower rotational dynamics. 
A host–guest type of interaction widely explored to obtain large supramolecular 
structures involves cyclodextrins (CDs) and poly(β-CD)s (poly- β-CDs). CDs are 
naturally occurring, water-soluble, toroidally shaped oligosaccharides with a 
truncated cone-shaped hydrophobic cavity that can host a variety of organic 
compounds, especially those carrying a lipophilic group. Gd3+ complexes bearing 
hydrophobic substituents such as adamantyl, cyclohexyl, or phenyl moieties in their 
structure have been shown to be able to form inclusion adducts with β-CD (β-CD is a 
CD made up of seven sugar units) with high binding constants and remarkable 
relaxivity enhancement[18–21]. 
The ditopic Gd3+ complex was specifically designed to form host–guest adducts with 
β-CDs and poly-β-CDs, as the adamantyl moiety is known to interact strongly with 
the β-CD cavity [22, 23]. To the best of our knowledge, only a few Gd3+ chelates bearing 
an adamantyl moiety have been reported[18,24]. A detailed relaxometric 
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characterization of the complex was performed in aqueous solution by investigating 
the 1H relaxivity dependence on pH, temperature, and magnetic field strength. The 
noncovalent interaction with both β -CD and poly-β-CD was evaluated by using the 
proton relaxation enhancement (PRE) method, and a detailed relaxometric study on 
the resulting host–guest adducts was conducted. Furthermore, to assess the possible 
application of such a system as an MRI contrast agent, and thus its stability in the 
presence of endogenous competitive species, the interaction with HSA was also 
investigated. Moreover, an in vivo test on B16-tumorbearing mice was performed by 
acquiring magnetic resonance images at 1 T over a period of 24 h. 
 
3.1 Synthetic procedure 
 
 
 
Scheme 3.1: Synthesis procedure to obtain LAd; i) H2, Pd/C 10%, MeOH, rt; ii) Cl2CS, 
CH2Cl2/NaOH 1 M, rt; iii) CH2Cl2, rt; iv) TFA, CH2Cl2, rt. 
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Starting from the AAZTA-like dimer II, describred in the previous chapter, we used it 
as a bifunctional chelating agent for the development of larger assemblies [17]. The 
synthetic route towards the desired ditopic Gd2LAd complex (Scheme 1) starts from the 
reduction of the nitro-group of I to amine (II), and then with the amine conversion into 
an isothiocyanate group using thiophosgene, obtaining IV. Finally, the reaction 
between IV and (1-adamantyl) methylamine in CH2Cl2 under mild basic conditions to 
afford V. The intermediate V was then deprotected by using a 1:1 mixture of 
trifluoroacetic acid (TFA) and CH2Cl2, yielding the final ligand LAd. Both LAd and its 
protected form V were fully characterized by mass spectrometry and NMR 
spectroscopy. Although ditopic and/or multimeric Gd3+ complexes are widely 
investigated [25–27], not many of them are functionalized with a reactive or a target-
specific moiety [17, 28–32]. For example, we have recently reported a series of ditopic Gd3+ 
complexes bearing hydrophobic moieties or a functional group obtained through a Ugi 
four-component reaction, including a study of the interaction between the octadecyl 
derivative and HSA [32]. However, in that case, the use of the less efficient GdDOTA-
monoamide complexes led to results hampered by the presence of only one 
coordinated water molecule in slow exchange with the bulk. 
 
 
3.2 1H relaxometric study 
The Gd3+ complex was prepared by adding small volumes of a stock solution of 
Gd(NO3)3 to a solution of LAd while maintaining the pH at 6–7 with dilute NaOH. The 
complexation process was monitored by measuring the change in the longitudinal 
water proton relaxation rate (R1) as a function of the amount of Gd3+ added. The slope 
of the straight line obtained corresponds to the relaxivity (r1) of the complex, i.e., the 
R1 enhancement per millimolar concentration of paramagnetic metal at a given 
temperature and magnetic field strength (typically 298 K/310 K and 20 MHz). The r1 
value of the ditopic complex at 20 MHz and 298 K was found to be 16.7 mM-1 s-1 (per 
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Gd atom), over two times greater than that of the corresponding monomeric 
GdAAZTA complex [15, 16]. This corresponds to an enhancement of 135 %, which can 
be largely attributed to the increase in molecular size, which translates into a 
corresponding increase of τR. In fact, the short linkers connecting the two metal 
chelates and the adamantly moiety to the central aromatic group are expected to 
minimize the flexibility of the system and favor long rotational correlation times in 
both the free form and the bound form. 
To get more insight, the 1H nuclear magnetic relaxation dispersion (NMRD) profiles 
of Gd2LAd were recorded in aqueous solution at pH 7 and at 283, 298, and 310 K (Fig. 
1, left). The relaxivity per gadolinium atom is comparable to or even higher than that 
of other Gd3+ dimers [25–27], and is almost unchanged over a large range of magnetic 
fields (r40 MHz = 17.6 mM-1 s-1 ; r70MHz 17.4 mM-1 s-1), thus being interesting for 
applications in high-field MRI studies. 
 
Figure 3.1: left) 1H nuclear magnetic relaxation dispersion (NMRD) profiles of 
Gd2LAd (see Scheme 3.1 for the structure) at 283, 298, and 310 K; right)  r1 as a function 
of temperature for Gd2LAd (20 MHz, pH 7). The dashed line represents a simple fit 
to a monoexponential function to confirm the fast-exchange conditions. 
 
94 
 
Moreover, the r1 value (20 MHz, 298 K) remains constant over a large pH range (4–11; 
Figure 3.2), indicating its stability towards acid-catalyzed and base-catalyzed 
dissociation. 
The experimental data were then analyzed by fitting the data to the established theory 
for paramagnetic relaxation, using the well-known Solomon–Bloembergen–Morgan 
(SBM) equations and Freed’s model for innersphere and outer-sphere contributions to 
the proton relaxivity, respectively [2, 3].  
 
Figure 3.2: Dependence of the relaxivity of Gd2LAd on pH (20 MHz; [Gd2LAd] = 0.105 
mM). 
There are several parameters that enter in the description of the magnetic field 
dependence of r1, but some of these can be set at standard values. The number of 
coordinated water molecules (q) was fixed to two, the distance of closest approach of 
the outer-sphere water molecules to Gd3+ was set to 4.0 Å a typical value for small 
metal chelates, and for the relative diffusion coefficient (D) the standard value of 2.24 
x 10-5 cm2 s-1 (298 K) was used. The Gd–water proton distance (rGd–H) and τR are 
parameters that are strongly correlated, and then the former is generally fixed. 
According to a pulsed electron–nuclear double resonance study by Caravan et al. [33], 
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the rGd–H values for selected DTPA- and DOTA-like Gd3+ complexes fall in the range 
3.0–3.2 Å. The best results were obtained by fixing rGd–H at 3.0 Å.  
As a function of temperature, r1 follows an exponential dependence, as typical for 
gadolinium-based systems under a fast-water exchange regime (Fig. 1, right). We then 
used for the exchange lifetime the same value reported for [Gd(AAZTA)(H2O)2]- , i.e., 
298 sM = 90 ns [15, 16]. Nevertheless, the relaxivity is not affected by this parameter, and 
the result of the fit does not change for values of sM in the range 50–150 ns. We then 
used as adjustable parameters Δ2 , sV, and sR. The electronic relaxation parameters, Δ2 
and sV, are rather similar to those of the monomer, indicating that the typical 
coordination cage of AAZTA is retained in the ditopic complex. The rotational 
correlation time is of the order of 220 ps (at 298 K), about three times longer. Although 
the fit can be considered rather satisfactory, it is not of very high quality, especially for 
the data at 283 K. 
Much better results are obtained using the Lipari–Szabo approach for the description 
of the rotational dynamics. This model allows one to take into account the presence of 
a certain degree of internal rotation superimposed on the overall tumbling motion [34, 
35]. These two types of motion, a relatively fast local rotation of the coordination cage 
about the linker to the central aromatic scaffold superimposed on the global 
reorientation of the complex, are characterized by different correlation times: τRL and 
τRG, respectively. The degree of correlation between global and local rotations is given 
by the parameter S2 , which takes values between 0 (completely independent motions) 
and 1 (entirely correlated motions). A five-parameter (Δ2, τV, τRL, τRG, and S2 ) least-
squares fit of the data was performed. The best-fit parameters for Gd2LAd are listed in 
Table 1 and are compared with those for the parent complex [Gd(AAZTA)(H2O)2]- . 
The correlation times for the local and global rotations differ by only a factor of 3, hence 
confirming the low level of rotational flexibility of theditopic complex. This is also 
evidenced by the large value of the order parameter S2 . 
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3.2.1 Supramolecular adducts with β-CD and poly-β-CD                                                          
As mentioned already, an alternative route for increasing the relaxivity consists in the 
formation of host–guest noncovalent interactions between suitably functionalized 
complexes and slowly tumbling substrates. A major advantage is that the structural 
integrity of the complex is preserved, and then the unbound form can be easily 
separated from the free from. In addition, the association constant can be modulated 
as it depends on the physicochemical properties of the targeting group. The relaxivity 
of the supramolecular structure depends on several properties of the paramagnetic 
guest: the number of bound water molecules (q), their rate of exchange with the bulk, 
and the degree of rotational mobility of the complex in the bound form, which is also 
correlated with the compactness and stereochemical rigidity of the free complex. 
Finally, also the nature of the pendant group dictates the strength of the interaction.  
 
Figure 3.3. Left: Water proton relaxation rate of a 0.08 mM aqueous solution of 
Gd2LAd as a function of increasing amounts of b-cyclodextrin (β-CD) (20 MHz, 298 
K). Right: 1H NMRD profiles of Gd2LAd-β-CD at 283, 298, and 310 K. 
The presence of an adamantyl moiety in the ditopic Gd2LAd complex allows its strong 
interaction with the hydrophobic cavity of β-CDs: for such adducts, high affinity 
constants (KA = 103–104 M-1) have often been reported [13]. In the context of this work, 
the properties of the adducts between Gd2LAd and either monomeric β-CD or high 
molecular weight poly-β-CD were investigated through the well-established 1H PRE 
technique. This consists in measuring the variation in R1 for increasing concentrations 
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of the host. With this method, the binding parameters KA, n (the number of equivalent 
and independent binding sites), and rb1(the relaxivity of the resulting supramolecular 
adducts) can be assessed. To this end, a dilute solution of Gd2LAd was titrated with β-
CD, at 20 MHz and 298 K, and the least-squares fit of the R1 versus β-CD concentration 
binding isotherm (Figure 3.3, left) enabled us to calculate the affinity constant [KA = 
(1.05 ± 0.09) x 104 M-1] and the relaxivity of the adduct (rb1 = 21.4 ± 0.1 mM-1 s-1). The 
formation of the inclusion compound was then accompanied by an increase of r1 of 29 
% relative to the isolated complex, which reflects the slowing down of molecular 
tumbling. The analysis of the NMRD profiles indicates that both the local rotational 
correlation time and the global rotational correlation time (Table 1) are more than 
doubled as compared with the free dimer, whereas the S2 value is sensibly reduced 
(from 0.66 to 0.23), suggesting great flexibility of the adamantly moiety in the β-CD 
cavity.  
 
Figure 3.4: Left) Water proton relaxation rate of a 0.05 mM aqueous solution of 
Gd2LAd as a function of increasing amounts of poly-β-CD (20 MHz, 298 K). Right) 
NMRD profiles of Gd2LAd–poly-β-CD at 298 and 310 K. 
An analogous binding interaction was exploited to form larger supramolecular 
assemblies using as the host a polymer of β-CD with a molecular mass of 
approximately 15 kDa. In this case up to 13 Gd2LAd units can be loaded into the β-CD 
cavities to form a final system (Gd2LAd–poly- β-CD) with a molecular mass of about 34 
kDa. Each of the 13 β-CD units of poly- β-CD can bind the adamantyl moiety of 
Gd2LAd. This linear polymer is characterized by nearly equivalent binding sites and, 
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as a consequence, will affect the rotational dynamics of each bound chelate 
approximately equivalently. 
Consequently, the interaction of Gd2LAd with poly-β-CD reproduces, to a first 
approximation, a simple 1:1 binding model (Figure 3.4). The data were fitted to a 
simple model that considers the presence of 13 equivalent and independent binding 
sites, yielding the values of the association constant [KA = (1.27 ± 0.13) x 104 M-1] and 
the relaxivity (rb1 = 33.9 ± 0.3 mM-1 s-1) for the bound ditopic complex.  
The relaxivity enhancement is then of the order of 100 % over the dimer and 61 % as 
compared with Gd2LAd–β-CD. It is worth stressing that the rb1 value represents an 
average value and not the absolute value of a well-identified ditopic chelate. The 
NMRD profiles were recorded at two temperatures under conditions ensuring that 
more than 98 % of the chelate was bound to the macromolecular substrate (Figure 3.4, 
right). Fitting the profiles to the SBM theory (including the Lipari–Szabo model) 
affords the parameters listed in Table 3.1. 
The marked decrease in molecular tumbling is reflected in the formation of relaxivity 
peaks centered at about 40 MHz, distinctive of slowly rotating systems. However, an 
increase of the local degree of rotation of the discrete dimer at the binding site also 
occurs, which limits the relaxivity. 
This is shown by the decrease of S2 (from 0.29 for Gd2LAd–β-CD to 0.17 for Gd2LAd –
poly-β-CD) and by the larger difference between τRG (2.3 ns) and τRL (410 ps). 
A comparison between the relaxivity values of the supramolecular adducts Gd2LAd–β-
CD and Gd2LAd–poly-β-CD and those measured for related paramagnetic systems 
underlines the fact that the rb1 values reported here are the highest for chelates 
functionalized with a single hydrophobic group [18, 20]. On the other hand, Gd3+ 
complexes of DTPA, DOTA, or DO3A bearing three cyclohexyl or benzyloxy groups 
were found to form inclusion compounds with β-CD or poly-β-CD of even higher 
relaxivity [19]. This can be explained on the basis of an increased rigidity of the systems 
(greater τRL) due to multisite interactions that cannot occur in the case of the 
monoadamantyl-substituted bimetallic chelate. 
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3.2.2 Interaction with HSA 
 
The presence of a hydrophobic pendant arm on the Gd3+ complex makes possible 
noncovalent interactions with hydrophobic binding sites on HSA. The noncovalent 
binding with plasma proteins is generally exploited to increase the lifetime of the 
paramagnetic probe in the vascular system, for angiographic MRI applications, and to 
expand the time window for imaging. The interaction is accompanied by a strong 
relaxivity enhancement associated with the reduced tumbling rate (lengthening of R) 
of the adduct [1, 4, 5, 13]. Like for the case of-CD, the binding parameters were 
determined according to the PRE method by measuring R1 as a function of the 
concentration of added protein (Figure 3.5, left). Fitting of the experimental data was 
performed assuming the presence of one equivalent and independent binding site (n 
= 1), even though the presence of multiple affinity sites on HSA cannot be excluded.  
 
 
 
Figure 3.5: Left) Water proton relaxation rate of a 0.05 mM aqueous solution of 
Gd2LAd as a function of increasing amounts of poly-β-CD (20 MHz, 298 K). Right: 
NMRD profiles of Gd2LAd–poly-β-CD at 298 and 310 K. 
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In this way, we could estimate the value of the thermodynamic association constant, 
which was rather similar to that with -CD [KA = (1.2 ± 0.8) x 104 M-1], and the 
relaxivity of the resulting paramagnetic metalloprotein (rb1 = 41.4 ± 1.1 mM-1 s-1). The 
NMRD profiles of the Gd2LAd –HSA adduct were measured at 298 and 310 K (Figure 
3.5, right) for a 0.07 mM solution of Gd2LAd in the presence of 1.0 mM HSA. Under this 
condition, more than 99 % of the ditopic complex is bound to the protein. The data 
were analysed only in the high field region because of the known limitations of the 
SBM theory to completely account for the behavior of slowly rotating systems at low 
magnetic field strengths [13]. The rb1 value represents an additional increase of about 20 
% compared with the relaxivity of Gd2LAd–poly-β-CD and is comparable to that 
reported for the commercial blood pool contrast agent MS-325 (rb1 = 49 mM-1 s-1) [36]. 
The best-fit parameters (Table 3.1) indicate that the relaxivity of the adduct is markedly 
limited by the poor correlation between global and local rotational motions. A more 
pronounced degree of immobilization by protein binding would make it possible to 
attain a further, large relaxivity enhancement. It is worth noting that even a 
nonoptimal rate of exchange could hamper the achievement of higher relaxivity; 
however, the decrease of rb1 with increasing temperature suggests that this parameter 
is not a dominant factor. 
Paramter Gd2LAd Gd2LAd-β-CD Gd2LAd-poly-β-CD Gd2LAd-HSA GdAAZTAa 
298r1p 
(mM-1 s-1)b 
16.7 21.6 33.9 41.4 7.1 
Δ2 
(1019 s-2) 
2.5 1.2 1.3 1.4 2.2 
298τV  
(ps) 
31 44 37 21 31 
298kex 
(106 s-1) 
11.1c 11.1c 11.1c 11.1c 11.1 
298τRG 
(ns) 
0.29 0.62 2.3 28 0.074 
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298τRL  
(ps) 
107 227 410 479 - 
S2 0.66 0.29 0.17 0.10 - 
qc 2 2 2 2 2 
rGdH 
(Å)c 
3.0 3.0 3.0 3.0 3.1 
a 
(Å)c 
4.0 4.0 4.0 4.0 4.0 
298D 
(10-5 cm2 s-1)c 
2.24 2.24 2.24 2.24 2.24 
 
Table 3.1: Best-fit parameters obtained by analysis of the 1H nuclear magnetic 
relaxation dispersion profiles for Gd2LAd (See scheme 3.1 for the structure) and his 
adducts with β-CD, poly-β-CD and human serum albumin (HSA); a From [6,7]; b at 
20 MHz; c fixed in the fitting procedure. 
 
3.3 In vivo MRI analysis 
 
In vivo tumor, liver, and kidney accumulation of Gd2LAd was investigated by Dr Eliana 
Gianolio and Francesca Arena through a 24-h acquisition of magnetic resonance 
images at 1 T of B16-tumor-bearing mice at the Department of Molecular 
Biotechnology and Health Sciences,Molecular Imaging Center, Università di Torino. 
Control experiments were conducted by using the commercial nonspecific contrast 
agent ProHance© [gadolinium 10-(2-hydroxypropyl)-DO3A] at the same time intervals 
and concentration (Figure 3.5). We subcutaneously injected approximately 1 x 106 B16 
murine melanoma cells into C57Bl/6 female mice (6–7 weeks old). Tumor growth was 
monitored, and the mice underwent MRI analysis 10–12 days after inoculation, when 
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the tumor dimensions were about a few hundred cubic millimeters. A strong signal 
enhancement in the tumor region was noted up to 50 min after the administration of 
Gd2LAd (0.05 mmol/kg), which was not observed when ProHance© was 
administered.Moreover, the signal enhancement in the tumor appears to be 
significantly high (approximately 40 %) even 24 h after the administration of the probe. 
The enhanced tumor retention observed after the administration of Gd2LAd is likely 
related to its high affinity towards serum albumin. 
The binding with serum proteins allows prolonged retention of the paramagnetic 
probe in the vascular system and its gradual accumulation in the tumor region on the 
basis of the well-known enhanced permeability and retention effect [37]. Albumin-
bound MRI contrast agents pass through the highly permeable blood vessels in tumor, 
but not in normal tissues, and do not diffuse back into blood capillaries or end up in 
the lymphatic system. In contrast, the neutral and nonspecific ProHance© complex, 
which is not able to bind to serum proteins, is rapidly eliminated from the vascular 
system and does not accumulate in the tumor region. The signal enhancements 
observed for liver and kidney suggest a preferential renal elimination of Gd2LAd, as 
expected for low molecular weight gadolinium-based contrast agents. 
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The mean signal enhancement percentage in kidneys reaches a peak during the first 
30 min, with a subsequent decrease after 6 and 24 h due to the renal elimination (see 
the electronic supplementary material). 
Figure 3.5: Top) Comparison of the signal enhancement in tumor, liver, and kidneys, 
calculated from the mean signal in the region of interest with respect to the 
precontrast images, after intravenous injection of 0.05 mmol/kg Gd2LAd (top left) 
and ProHance (top right). Bottom) Axial T1-weighted magnetic resonance images 
recorded at 1 T on a mouse before (proton relaxation enhancement, PRE) and after 
(30 min, 6 h, and 24 h) the administration of 0.05 mmol/kg Gd2LAd (A) and ProHance 
(B). The tumor region is highlighted with a red circle. 
 
Despite the lipophilic properties of Gd2LAd and its quite strong interaction with serum 
albumin, a very low hepatic accumulation has been observed [38]. 
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3.4 Conclusions 
 
Figure 3.6: 1H relaxivity values of GdAAZTA  and Gd2LAd and its supramolecular 
adducts with b-CD, poly-b-CD, and HSA (20 MHz, 298 K) 
 
A novel ditopic Gd3+ complex bearing a hydrophobic adamantly moiety, based on two 
stable and q = 2 GdAAZTA-like complexes, has been synthesized and characterized. 
The 1H relaxometric properties and the ability to form supramolecular adducts with 
CD, poly-β-CD, and HSA have been investigated in detail. Gd2LAd has several 
excellent properties which make it a promising highly efficient MRI probe: (1) each 
Gd3+ ion possesses two inner-sphere water molecules characterized by a sufficiently 
fast rate of exchange; (2) it is stable over a wide pH range; (3) it has a good degree of 
compactness and limited rotational flexibility, which results in a τR value nearly ideal 
for MRI applications at high field strengths (1.5–3.0 T); (4) it is endowed with a strong 
ability to interact noncovalently with a number of substrates of increasing complexity 
(KA ~ 104 M-1), thus affording large relaxivity enhancements. The relaxivity values per 
gadolinium atom show a constant increase from Gd2LAd to Gd2LAd–HSA, 
corresponding to an enhancement of up to approximately 250 %, as illustrated in 
Figure 3.6. In conclusion, as the CD cavity may also host drug molecules, properly 
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functionalized targeting vectors, or optical dyes, the optimized Gd2LAd complex has 
good potential to be used in CD-based probes in association with a vector or a dye for 
molecular imaging applications or in association with a drug for theranostic or 
pharmaceutical uses. 
 
3.5 Experimental part 
Synthesis of III 
10% Pd/C (15 mg) suspended in water (1 mL) was added to a solution of II (150 mg; 
0.106 mmol) in MeOH (10 mL). The mixture was stirred overnight under H2 
atmosphere and then filtered. The filtrate was evaporated in vacuo affording pure III 
(136 mg; 93%). TLC (silica gel 60 F254, petroleum ether/EtOAc 8 : 2, detection: UV 254 
nm): Rf 0.05. 1H-NMR (CDCl3) 500 MHz d = 7.12 (bs, 2H, NH), 6.79 (bs, 1H, CH), 6.61 
(bs, 2H, CH), 4.14 s, 4H, CH2OCO), 3.66 (s, 8H, CH2CO), 3.22 (s, 8H, CH2CO), 3.04 (d, 
4H, J = 14.3 Hz, CH2C), 2.74 (d, 4H, J = 14.3 Hz, CH2C), 2.87–2.61 (m, 8H, CH2CH2), 
1.37 (s, 36H, CH3), 1.36 (s, 36H, CH3). 13C-NMR (CDCl3) 125 MHz d = 172.8, 170.6 (CO), 
153.2 (NHCOO), 148.4 (C), 139.5 (2C), 100.1 (2CH), 98.7 (CH), 81.0, 80.8 (CCH3), 67.5 
(CH2OCO), 63.1 (C), 62.1–62.0 (CH2CO), 58.7, 51.4 (CH2cycle), 28.2, 28.1 (CH3). ESI+-MS 
(m/z): 1379.43 [M + H]+; calc for C68H116N9O20: 1378.83.  
 
 
Synthesis of IV 
A solution of thiosphogene (10.5 μL; 0.138 mmol) in dry CH2Cl2 (2 mL) was added 
drop wise in 2 min to a ice-bath cooled mixture of III (98.5 mg; 0.106 mmol) in 
saturated NaHCO3 (5 mL) and CH2Cl2 (5 mL), under vigorous magnetic stirring. The 
ice-bath was removed after 5 min and the suspension was stirred for 2 h at room 
temperature. The organic phase was separated and extracted with water (3 x 10 mL); 
then the organic phase was dried over Na2SO4, filtered and evaporated to yield a 
yellow solid. TLC (silica gel 60 F254, petroleum ether/EtOAc 8 : 2, detection: UV 254 
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nm): Rf 0.29. 1H-NMR (CDCl3) 500 MHz d = 7.41 (bs, 2H, CH), 7.20 (bs, 1H, CH), 7.15 
(bs, 2H, NH), 4.21 (s, 4H, CH2OCO), 3.69 (s, 8H, CH2CO), 3.25 (s, 8H, CH2CO), 3.09 (d, 
4H, J = 14.3 Hz, CH2C), 2.87 (d, 4H, J = 14.3 Hz, CH2C), 2.70–2.64 (m, 8H, CH2CH2), 
1.43 (s, 36H, CH3), 1.42 (s, 36H, CH3). 13C-NMR (CDCl3) 100 MHz d = 172.8, 170.4 (CO), 
153.1 (NHCOO), 140.0 (C), 128.0 (C), 110.3 (CH), 106.7 (CH), 81.3, 81.0 (CCH3), 67.5 
(CH2OCO), 63.2 (C), 62.3, 62.1 (CH2CO), 59.0, 51.6 (CH2cycle), 28.2, 28.0 (CH3). ESI+-MS 
(m/z): 1421.38 [M + H]+; calc for C69H114N9O20S: 1420.79. 
 
Synthesis of V 
A solution of (1-adamantyl)methylamine (33 mg, 0.199 mmol) in dry CH2Cl2(2 mL) 
was added to a solution of IV (243 mg, 0.153 mmol) and Et3N (97 μL, 0.701 mmol) in 
dry CH2Cl2 (10 mL) under an N2 atmosphere. The mixture was stirred overnight at 
room temperature, and then it was evaporated in vacuo. The crude product was 
purified by column chromatography (SiO2, 7:3 petroleum ether/EtOAc), yielding V as 
a yellow oil (124 mg, 0.109 mmol, 71 % yield). 1H NMR (500 MHz, CD3Cl): d 7.58 (br s, 
2H, CHAr ), 7.29 (s, 1H, CHAr ), 7.17 (br s, 2H, NHCO), 6.47 (br s, 2H, NHCS), 4.22 (s, 
4H, CH2O), 3.25 (s, 16H, CH2C=O), 3.10–2.64 (m, 16H, CH2Cy), 2.04–1.51 (m, 13H, 
CHAd ), 2.02 (s, 2H, CH2Ad), 1.42 (br s, 72H, CH3). 13C NMR (125 MHz, CDCl3): d 172.0, 
170.8 (COOt-Bu ), 153.1 (NCO), 140.4 (CArq), 108.2 (CHAr ), 105.9 (CHAr ), 81.0, 80.9 
(CCH3), 67.9 (CH2O), 63.3 (CCyq), 62.3, 62.1 (CH2CO), 59.0, 51.6 (CH2Cy), 41.9 (CH2Ad), 
37.1, 34.1, 21.1, (CAd ), 28.3, 28.2 (CH3). ESI+-MS: m/z 1,587 = [M + H]+, 794 = [M + 
2H]2+ calc for C80H133N10O20S, 1,587.02). 
 
Synthesis of LAd 
TFA (3 mL) was added dropwise to a solution of V (124 mg, 0.0782 mmol) in CH2Cl2 
(3  mL). The mixture was stirred at room temperature overnight and then evaporated 
in vacuo. The solid residue was washed twice with Et2O (10 mL) and isolated by 
centrifugation. Then it was dried in vacuo, resulting in LAd as its trifluoroacetate salt. 
HPLC analysis: H2O/0.1 % TFA (solvent A) and CH3OH/0.1 % TFA (solvent B) 
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starting from 100 % solvent A for 5 min and then with a gradient to 100 % in 11 min at 
a flow rate of 1 mL min-1 over a total run of 20 min; retention time 15.9 min. 1H NMR 
(500 MHz, D2O) d 7.37 (br s, 2H, CHAr ), 7.19 (br s, 1H, CHAr ), 4.18 (s, 4H, CH2O), 5.28 
(s, 16H, CH2C=O), 2.80–2.57 (m, 16H, cycle), 1.96 (s, 2H, CH2Ad), 1.93–1.51 (m, 
13H,CH/CH2MeAd). 13C NMR (125 MHz, D2O): d 181.0 (CS), 180.5, 179.3 (COOH), 155.3 
(NCO), 137.8, 120.1 (CAr ), 118.2, 115.4 (CHAr ), 66.2 (CH2O), 64.3 (CH2C=O), 63.0 (CqCy), 
60.6, 56.6 (CH2Cy), 57.9 (CH2Ad), 39.9, 39.7, 36.6, 36.5, 28.1 (CAd ). ESI+-MS: m/z 1,138 
[M + H]+, 569 [M + 2H]2+ (calc for C48H69N10O20S, 1,138.17). 
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4. AAZTA-dimer functionalization as a 
multimodal optical-MRI imaging reporter 
 
The prevalence of age-associated neurodegenerative diseases is increasing rapidly. 
About 40 million people worldwide are affected by diseases like Alzheimer’s Disease 
(AD) or Parkinson’s Diseases (PD). Due to the ageing population, their incidence is 
expected to triple in the next forty years. This creates an urgent need for early diagnosis 
of the disease to enable treatment at an early stage. In spite of extensive research in the 
field, the cause and progression of such diseases is still not well understood. 
Neurodegenerative processes are closely related to the alterations of the brain 
network, for example reduced connectivity between the hippocampus and other 
regions such as prefrontal cortex and cingulate cortex [1]. One possible approach to 
successful therapy refers to the brain’s remarkable ability to change and reorganize 
itself, termed brain plasticity. It was long thought that brain plasticity declined with 
age. However, recent studies demonstrated that this is not the case, even in the early 
stages of disease [2]. Consequently more extensive studies are needed to understand 
the mechanisms underlying these processes. The methodology to investigate brain 
connectivity and plasticity has made substantial progress in the last few years. Newly 
developed animal models for neurodegenerative diseases in combination with 
improved neuroimaging technologies now provide researchers with unique tools to 
study disease processes and to investigate preclinically the effects of potential 
treatments in order to acquire knowledge that will ultimately inform clinical practise 
[3,4]. In addition to the current post-mortem techniques scientists will be able to take 
advantages of different less- or non-invasive modalities. 
Nevertheless, none of the developed methods is so far able to deliver complete 
information on this issue. The most commonly used in vivo imaging techniques in 
animal models are positron emission tomography (PET) and MRI, each of which has 
its own advantages and disadvantages. Whereas the former suffers from poor spatial 
resolution, the latter is more limited in the functional and neurochemical 
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measurements it is currently capable of. [5,6]. Diffusion tensor imaging (DTI) is the most 
popular MRI technique widely used in the clinic and providing a sensitive method to 
detect white matter changes in subjects with AD. Unfortunately, it seems that the 
method is not reliable for the investigation of the grey matter for example the neuronal 
connections present in the brain cortex [7]. 
An ideal strategy would be to develop methods that combine spatiotemporally-
resolved MR imaging with other invasive neuroscientific modalities. Manganese-
enhanced MRI (MEMRI) represents one of the approaches undertaken towards in vivo 
studying of neuronal connectivity by means of MR imaging [8]. However, difficulties 
in understanding manganese transport processes, due to their multi-synaptic nature, 
as well as the potential toxicity of the Mn2+ in the tissue, restricts its applicability [9,10]. 
Another promising approach which could be developed is one where paramagnetic 
tracers share transport properties with traditional monosynaptic histological markers. 
Recent attempts to conjugate paramagnetic Gd3+ complexes with classical 
neuroanatomical tracers such as biocytin, cholera toxin subunit B (CTB) or dextran 
amine have demonstrated the potential of such systems to act as contrast agents, thus 
offering an excellent alternative to MEMRI [11-13]. 
In this chapter we discuss the development of a multi-track methodology for 
longitudinal investigations of the monosynaptic connections between specific brain 
areas using MR and optical imaging techniques in combination with the other 
neuroscientific modalities. In particular, we used dextran amine as it is extensively 
used in neuroanatomical research as a core molecule conjugated to MR and optical 
reporters and because of two other important properties [14]. First, unlike CTB and 
other retrograde tracers, dextran is transported predominantly anterogradely 
(labelling begins at the dendrites and cell bodies and the dye is transported out to the 
axons and their terminals). Very often this type of transport is preferable in 
neuroanatomical research because it enables the projection targets of individual or 
groups of cells to be charted within the central nervous system. Second, in contrast to 
biocytin and many other “fast” tracers where the labelling occurs in 24 h, dextran 
belongs to the group of “slow” transported agents. Such types of neuronal tracing 
could be preferable for different kinds of longitudinal studies in vivo. 
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Scheme 4.1: Structure of GdL1. 
Tetramethylrhodamine was used as an optical reporter for the evaluation of the 
cellular uptake via fluorescence microscopy and additional histological control of 
cellular transport. The  bimetallic Gd3+  AAZTA-like ligand already discussed in 
Chapter 3 was attached to a dextranerhodamine conjugate through a thiourea linkage 
(Scheme 4.1). The relaxometric behaviour of the dual-imaging probe was compared 
with the one relative to the monetallic Dextran-TMR-GdL1 developed by Mamedov et 
al [13]. 
 
4.1 Synthetic procedure 
Conjugation of the fluorescent dye to dextran was carried out by the reaction of 
dextran amine with 2 eq of tetramethylrhodamine isothiocyanate in water/DMF 
solution at pH 8.5 resulting in Dextran tetramethylrhodamine (Dextran-TMR). An 
excess of the fluorophore was used to avoid or reduce the amount of the unreacted 
dextran which is difficult to separate from the reaction mixture. The conjugate was 
purified using a Minimate ultrafiltration device (Pall Life Science.) to remove excess of 
TMR. This part of the synthesis was performed in Tubingen by Dr. Mamedov group. 
For the synthesis of Dextran-TMR-Gd2L2, isothiocyanate containing dimer [15] was 
conjugated to Dextran-TMR in DMF/carbonate buffer at pH 9. In particular, to a 
solution of Dextran-TMR (30 mg, 0.003 mmol) in DMF (5 mL) and K2CO3 1M (5 mL), 
DIPEA (5,2 mL, 0.03 mmol) and HCl 1M were added to bring the pH to 9. Then, solid 
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Gd2L2 (38,5 mg, 0.03 mmol) was added to the reaction mixture which was stirred at 
room temperature for 36 h. The solution was then purified by ultracentrifugation using 
Vivaspin© (cut-off 5000 Da) and dried by lyophilisation obtaining pure Dextran-TMR-
Gd2L2 as a purple solid (47 mg). The Gd3+ concentration in the probes was calculated 
using the bulk magnetic susceptibility (BMS) shift method [16,17] and confirmed by ICP-
MS. Dextran:Gd3+ ratio was estimated to be 1:3.4 for Dextran-TMR-Gd2L2 (on average 
1.7 eq of complex per 1 eq dextran). 
 
 
 
Scheme 4.2: Synthesis of the dual-imaging probe Dextran-TMR-Gd2L2; i) TFA, 
CH2Cl2, rt, overnight; ii) Pd/C 10%, H2, MeOH, rt, 3h; iii) Cl2CS, CH2Cl2, NaHCO3 
sat, rt, 3h; iv) GdCl3, H2O, rt; v) DEX-TMR, DiPEA, DMF, K2CO3 1 M, rt, 48h.   
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4.2 Relaxometric measurements 
 
Two different probes were studied, containing a monomeric GdAAZTA system (GdL1) 
(ref Mamedov) in case of Dextran-TMR-GdL1 and dimeric (Gd2L2 ) in case of Dextran-
TMR-Gd2L2 . The two probes resulted also in different dextran: Gd3+ ratio that was 
estimated to be ~1:3 for Dextran-TMR-GdL1 and 1:3.4 for Dextran-TMR-Gd2L2 (on 
average 1.7 eq of dimeric complex per 1 eq dextran). 
Figure 4.1. 1/T1 NMRD profiles of aqueous solutions (pH = 7.4) of Dextran-TMR-
GdL1 (upper) and of Dextran-TMR-Gd2L2 (lower) at 298 K (triangles) and 310 K 
(circles). 
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The efficacy of the paramagnetic systems as MRI reporters was assessed by evaluating 
the magnetic field dependency of the relaxivity (r1p, the longitudinal relaxation 
enhancement of the water protons induced by a 1 mM concentration of the 
paramagnetic metal ions) in water at pH 7.4. The NMRD profiles (Figure 4.1) were 
measured at 298 and 310 K over a wide range of values, from 0.00024 to 11.7 T 
(corresponding to 0.01-500 MHz proton Larmor frequencies). The shape and 
amplitude of the profiles are characteristic of slowly tumbling Gd-based systems: a 
low fields region where r1p assumes a nearly constant value (~0.01-0.8 MHz), a 
dispersion around 1-3 MHz and a high field broad peak associated with the occurrence 
of a restricted molecular tumbling [18].  
 
Figure 4.2: r1 as a function of temperature for Dextran-TMR-GdL1 (left) and  Dextran-
TMR-Gd2L2 (right) (40 MHz, pH 7). For both the probes the behaviour is consistent 
with a fast water exchange regime system. 
 
 
 
Table 4.1: r1, r2 and r2/r1 (mM 1 s1 ) data measured in PBS buffer at 298 K. 
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The maxima are centred at about 40 MHz (1 T) for both systems and correspond to 
298r1p values of 36.1 mM-1 s-1 for Dextran-TMR-Gd2L2 and 24.6 mM-1 s-1 for Dextran-
TMR-GdL1 . The greater high field relaxivity enhancement and sharper peak for 
Dextran-TMR-Gd2L2 is indicative of a slower rotational dynamics. Longitudinal and 
transverse relaxation rates (R1 and R2) for both MRI probes were also measured at 7 T 
in PBS buffer (298 K; pH = 7.4) and the corresponding values are reported in Table 4.1 
 
Table 4.2: Selected best-fit relaxation parameters obtained from the analysis of the 
1/T1 NMRD profiles for Dextran-TMR-GdL1 and for Dextran-TMR-Gd2L2. 
 
 
4.3 Cell study 
 
Efficient cell internalization, effective labelling and transporting properties are 
essential for the tracer molecule to mark the neuronal tract. According to published 
data and the long experience of the neuroanatomists, dextran based markers are 
among the best tracers because of their detailed labelling properties [19]. However, 
there is strong dependence of cellular uptake and transporting properties on the nature 
of the applied fluorophore [20]. Most obviously the structure of the MR reporter should 
also influence the tracing ability of the final molecule. Therefore, in our cell studies we 
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examined how the MR reporter modifications would affect the labelling characteristics 
of the final molecules containing the same type of fluorophore. 
 
To investigate the cellular uptake of Dextran-TMR-Gd2L2 in comparison with Dextran-
TMR-GdL1 , differentiated mouse N18 neuroblastoma cells were incubated with 
solutions of tracers under physiological conditions in serum-containing medium for 
18 h. The results obtained by fluorescence microscopy clearly demonstrated that the 
nature of the MR reporter does indeed influence the uptake properties of the tracer 
(Figure 4.3). 
Figure 4.3: T1-weighted MR images of the differentiated N18 cells labelled with 20 
μM [Gd3+] of Dextran-TMR-GdL1 and Dextran-TMR-Gd2L2 (down) and analysis of 
the corresponding signal intensities (up). (Values represent mean ± SD, n = 76 
voxels. ***p < 0.001 statistically different compared to control, ***p < 0.001 statistical 
difference between both probes; ANOVA, Tukey’s post test.) 
 
Although both tracer molecules were taken up by the cells, they were located in 
different compartments. In fact, while Dextran-TMR-GdL1 was mainly concentrated in 
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cell bodies, Dextran-TMR-Gd2L2 was mainly observed in vesicles surrounding the 
nucleus and along the cell membrane. 
We assume that one of the reasons for such different behaviour could be the changes 
in lipophilicity due to the additional aromatic ring in the case of Dextran-TMR-Gd2L2 
which can influence the mechanism of uptake and accumulation. 
The spin-lattice relaxation times (T1) of N18 cells incubated with 20 mM solutions of 
each paramagnetic tracer were measured at a 3T horizontal scanner. The control cells 
were treated in the same way, but without the tracers. Cells were placed into 
Eppendorf tubes and T1 weighted images were acquired. Significant positive contrast 
enhancement was observed for the Dextran-TMR-Gd2L2 loaded cells in comparison to 
the control experiment (Figure 4.3). 
For Dextran-TMR-GdL1 the signal intensity was not much differing from the control. 
To explain the obtained results, the Gd3+ content of the cells from the MR experiments 
was determined in mineralised cell lysates by ICP-MS. Only a small amount could be 
found for Dextran-TMR-GdL1 (~0.07 nmol/106 cells). This is significantly above the 
detection limit of ICP-MS for such cell lysates (~0.01 nmol/106 cells) but obviously not 
sufficient to enhance contrast in the corresponding MR images. However, our previous 
experiments demonstrated considerable enhancement of the MR signal after 
incubation of the cells with 50 mM of Dextran-TMR-GdL1 [13]. In contrast, about 20-
fold more Gd3+ was seen for 20 mM Dextran-TMR-Gd2L2 (1.41 nmol/106 cells) in the 
present study. Thus, Dextran-TMR-Gd2L2 not only provides better signal enhancement 
due to its increased longitudinal relaxivity but also is internalised much better than 
Dextran-TMR-GdL1 into the cells. 
The exact reason for this behaviour remains unclear but the altered lipophilicity of the 
molecule might be involved as mentioned above. The in cellulo MR results indicate 
that the bis-macrocyclic derivative was able to deliver a stronger signal and thus might 
be better suited for in vivo experiments than the mono-macrocyclic tracer. 
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4.4 Conclusions 
 
Multimodal paramagnetic neuronal tracers with variable MR reporting moieties were 
developed. Physico-chemical characteristics were compared with in vivo behaviours, 
investigated by Dr. Mamedov group in Tubingen, between mono and bimetallic 
derivatives. It was found that the derivative containing the dimeric AAZTA moiety 
demonstrated stronger paramagnetic properties and as a result had a greater influence 
on the MR signal. It was also showed that as with the nature of the fluorophore, the 
structure of the MR reporter can influence cellular uptake and transport properties of 
dextran-based tracers. In spite of some differences in transport behaviour, both 
compounds resulted in MR signal enhancement in known targets of the primary motor 
cortex after an optimal 10 days post injection. Taking advantage of the multimodality 
of the developed tracers, MR results were confirmed by optical microscopy of the 
histological slices from the same animals. These encouraging results re-assure us that 
such optimized compounds can be used for particular neuroanatomical investigations. 
Depending on the final application, this technique can also be combined with other 
methods used in neuroscience (DTI, electrophysiology) providing essential 
information for in vivo whole brain longitudinal studies of monosynaptic connections 
under physiological and pathophysiological conditions. 
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5. Lipid nanoparticles including multimeric 
Gd3+ complexes 
 
 
As thoroughly debated in the introductive chapter, lipid nanoparticles as micelles and 
liposomes have been widely investigated and employed for the development of slow 
tumbling, and thus high relaxivity MRI probes. The aim of the work presented in this 
chapter is to synthesize mono- and multimeric amphiphilic AAZTA-based 
paramagnetic complexes, and investigate the capability of these systems of generating 
lipid nanoparticles. The relaxometric study on these lipidic nanoparticles was carried 
out in order to compare the ability  of the different multimeric anphiphilic probes to 
generate contrast with respect to the monomer. Moreover, this approach was aimed at 
understanding the rotational dynamics of these nanoprobes that have not been 
investigated so far. 
The critical point is the degree of correlation between local motion of the complex and 
global rotation of the nanoparticle. The idea was to design a slow tumbling system 
(slow global rotation), in which the paramagnetic amphiphilic probes are encapsulated 
into the nanoparticle (self-assembling micelles, mixed micelles, liposomes etc.) 
maintaining as higher as possible the local rigidity of the systems. This is because often 
slow tumbling systems doesn’t show the appropriate increase in terms of relaxivity 
expected for them, because of the decrease of local rigidity that affects this kind of 
systems.  
The synthesis and characterization of the probes described in this chapter (monomer, 
dimer and tetramer) is directed to investigate the possibility to increase the relaxivity 
of slow tumbling systems using multimeric paramagnetic complexes (higher local 
rigidity) instead of monomeric complexes and using a double aliphatic chain to allow 
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a more tight interaction between hydrophobic groups and thus a slower local rotation 
of the complexes. 
  
5.1 Synthetic procedure 
 
 
Scheme 5.1: Syntethic procedure to obtain the three mono- and multimeric 
amphiphilic probes; i) CH2Cl2, N2, 3h, rt; ii) H2, Pd/C 10%, MeOH, 3h, rt; iii) Cl2CS, 
CH2Cl2, NaHCO3 sat., 3h, rt; iv) H2NC12H25, CH2Cl2, overnight, rt; v) TFA, CH2Cl2, 
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overnight, rt; vi) HN(C12H25)2, CH2Cl2, N2 overnight, rt; vii) (CNH2CNH2)(C12H25)2, 
TEA, CH2Cl2, 40 °C, overnight. 
 
While the monomeric AAZTA-like bifunctional agent IX was employed for the 
synthesis of LI, the AAZTA-like dimer IV was used for the synthesis of LII and LIV. [1] 
In the all three cases the formation of the amphiphilic compounds was achieved 
through the formation of a thiourea bond between the isothiocyanate group of IX and 
IV and the amino group of 1-dodecilamine (for LI), 1,1-didodecilamine (for LII) and 
1,2-didodecil-1,2-ethylendiamine (for LIV). The reactions were carried out with a slight 
excess of the corresponding amines in dichloromethane and in mild basic conditions 
(pH 8-9) at room temperature for the synthesis of LI and LII and in a slight excess of IV 
and warm temperature (40 °C) to obtain LIV. Products X and XI were purified by 
column chromatography and deprotected with trifluoroacetic acid in dichloromethane 
yielding the final ligands LI and LII, while LIV was purified after t-butyl esters 
deprotection directly as free ligand trough dialysis. All the intermediate products and 
the final ligands obtained were fully characterized by 1H and 13C NMR. 
All the Gd3+ complexes were obtained through relaxometric titration with GdCl3, 
obtaining the three amphiphilic complexes GdLI, Gd2LII and Gd4LIV (Figure 5.1). 
 
 
 
Figure 5.1: Structures of GdLI (left), Gd2LII (centre) and Gd4LIV (right), obtained with 
Hyperchem software. 
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5.2 Relaxometric and DLS study 
 
5.2.1 Self-aggregated systems 
 
The relaxivity of GdLI, measured at 20 MHz and 310 K, shows a value of 29.0 mM-1 s-
1, consistent with comparable systems reported in literature[2]. The 1H NMRD profiles 
were recorded in aqueous solution at pH 7 and at 298 and 310 K (Figure 5.2).  
Is easy to see how the dependence of the relaxivity on magnetic field shows a peak 
that reach its maximum around 40-50 MHz. This kind of peak is typical of slow 
tumbling systems, and in this case, jointly with the high r1p for a monomeric complex, 
gives us the proof of the formation of a self-aggregated system.  
Figure 5.2: The 1H NMRD profiles of GdLI, pH 7, 298 (black dots) and 310 K (red 
dots), [Gd] = 1.09 mM. 
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This consideration was also confirmed trough Dynamic Light Scattering (DLS) 
analysis that display a value of 9.24 nm for the micelles in water solution (Figure 5.3). 
 
Figure 5.3: DLS analysis of a GdLI solution. 
The relaxometric data were analyzed using the Lipari-Szabo approach for the 
rotational dynamics. The presence of a local motion (τRL) superimposed to a global 
rotation (τRG) and the degree of correlation between them (S2 (0≤ S2≤1)) are the most 
important parameter to consider. The results are shown in Table 5.1. 
Parameter GdLI 
298r1p (mM-1 s-1)[b] 29.0 
Δ2 / 1019 s-2 1.50 
298τV / ps 44.2 
298kex / 106 s-1 12.5 
298τRg (ns) 2.4 
298τRl (ps) 130 
S2 0.43 
q [a] 2 
r / Å [a] 3.0 
a / Å [a] 4.0 
298D / 10-5 cm2 s-1 [a] 3.1 
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Table 5.1: Best fit parameters obtained from the analysis of 1H NMRD profiles of 
GdLI. 
 
Figure 5.4: Relaxivity decrease diluting a GdLI solution. 
We then tried to identify the critical micellar concentration (cmc) of this system, trough 
the measure of R1 in dilutedsolutions of the complex. Unfortunately, it was not 
possible to identify the cmc because, as shown in Figure 5.4, there’s not a significant 
change in the slope of the straight line that defines the relaxivity dependence to [Gd]. 
The cmc value for this system is likely too low to be measured.  
Even if the relaxivity of this system is in line with literature data, the behaviour of the 
r1p as a function of temperature was not expected. As clearly showed in Figure 5.2, the 
NMRD profiles recorded at two different temperatures (298 and 310 K) are almost 
superimposed. This behaviour may indicate some variation in the coordinated water 
molecules exchange rate. The AAZTA cage is characterized by a fast water exchange 
regime,[ref aazta] and for this reason a substantial decrease of the relaxivity with 
increasing temperature was expected. This phenomenon could be due to different 
factors, as the proximity of the self-aggregated paramagnetic complexes [2], or the 
decrease of the water exchange rate caused by structural features.    
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The next step of the study was the relaxometric characterization of Gd2LII , and its 
comparison with the monomeric GdLI.  
In Figure 5.5 the 1H NMRD profiles of a Gd2LII solution, at 298 and 310 K, are shown. 
 
Figure 5.5: NMRD profiles of Gd2LII at 298 (circles) and 310 K (triangles), pH 7, [Gd] 
= 0.44 mM.  
 
 
Figure 5.6: Relaxivity decrease diluting a Gd2LII solution. 
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For Gd2LII a r1p value of 36.6 mM-1 s-1 was obtained at 310K and 20 MHz. The value is 
slightly higher than that one obtained for GdLI, as expected for a dimeric complex. 
The relaxivity increase is probably due to the increased local rigidity of the system, 
caused by the dimeric structure and the double aliphatic chain. 
The profiles are quite similar to those for GdLI, showing a peak in the 40-50 MHz 
region, as expected for the self-aggregated system. Also for Gd2LII the profiles at two 
different temperatures are almost superimposed, likely implying some variation in the 
coordinated water molecules exchange rate. Also in this case the cmc of Gd2LII (Figure 
5.6), could not be determined as there is no significant change in the slope of the 
straight line at low concentrations.  
 
Figure 5.7: NMRD profiles of Gd4LIV at 298 (black dots) and 310 K (red dots), pH 7, 
[Gd] = 0.375 mM. 
 
Finally the NMRD profiles of Gd4LIV were measured, at 298 and 310 K (Figure 5.7). 
The r1p value obtained for Gd4LIV at 310 K and 20 MHz is 18.1 mM-1 s-1, quite low if 
compared to the two complexes previously discussed. Probably, at this Gd3+ 
concentration ([Gd4LIV] = 0.375 / 4 = 0.0937 mM) the complex doesn’t show any self-
aggregation, as confirmed also by the shape of the NMRD profiles, lacking of the 
typical peak for slow tumbling systems at 40-50 MHz.  
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Moreover, the variation of r1p with temperature is largely different to those measured 
for GdLI and Gd2LII. In this case increasing the temperature gives rise to a significant 
relaxivity decrease, as clearly showed in Figure 5.8. At the moment we cannot say if 
the lack of self-aggregation is due to the low complex concentration or, basically, to 
the structure of ligand. It is possible that, for a large complex with a bulky hydrophilic 
head, a double C12 aliphatic chain is too short to allow a micellar aggregation. 
 
Figure 5.8: r1p as a function of temperature for Gd4LIV, 20 MHz and [Gd] = 0.375 mM. 
 
5.2.2 Interaction with HSA 
 
Aliphatic chains are a widely exploited hydrophobic group for the formation 
supramolecular host-guest adducts with serum albumin. Thus, the capability of our 
amphiphilic Gd-complexes to generate inclusion compounds with HSA was 
investigated.  
Using the previously described Proton Relaxation Enhancement method, it was 
possible to determine the binding parameters KA, n, and rb1. To this end, a dilute 
solution of GdLI was titrated with HSA, at 20 MHz and 298 K (Figure 5.9). The least-
squares fit of the R1 versus HSA concentration binding isotherm enabled us to calculate 
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the affinity constant (KA = 7.94 x 104 M-1) and the relaxivity of the adduct (r1b = 56.9 
mM-1 s-1, 298K and 20 MHz), fixing the n value to 1.  
Figure 5.9: Water proton relaxation rate of a 0.046 mM aqueous solution of GdLI as 
a function of increasing amounts of HSA (20 MHz, 298 K). 
 
 
Figure 5.10: NMRD profiles of the GdLI-HSA inclusion compound at 298 (black 
circles) and 310 K (white triangles), pH 7 and [Gd] = 0.046 mM. 
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The formation of the inclusion compound was accompanied by an increase of r1 of 96% 
with respect to the isolated complex which reflects the slowing down of molecular 
tumbling. 
In Figure 5.10 the NMRD profiles of the GdLI-HSA inclusion compound are reported. 
A peak with maximum around 40-50 MHz can be clearly seen, suggesting the 
formation of the slow tumbling adduct. The trend of r1 vs temperature is still 
anomalous, as the profiles at two different temperatures are almost superimposed. 
 
 Figure 5.11: Water proton relaxation rate of a 0.066 mM aqueous solution of Gd2LII 
as a function of increasing amounts of HSA (20 MHz, 298 K). 
Figure 5.12: NMRD profiles of the Gd2LII-HSA inclusion compound at 298 (black 
dots) and 310 K (triangles), pH 7 and [Gd] = 0.066 mM. 
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Also the interaction between Gd2LII  and HSA was investigated, as reported in Figure 
5.11 and 5.12. 
A dilute solution of Gd2LII was titrated with HSA, at 20 MHz and 298 K, and the fit of 
the R1 versus HSA concentration binding isotherm allowed the determination of the 
affinity constant (KA = 5.04 x 104 M-1) and the relaxivity of the adduct (r1b = 64.1 mM-1 
s-1, 298K and 20 MHz), fixing the n value to 1. The formation of the inclusion compound 
was accompanied in this case by an increase of r1 of 81% with respect to the self-
aggregated form. The enhancement in terms of rb1 was remarkable, but the affinity 
constant for the inclusion compound is lower than for GdLI-HSA, although in this case 
the guest group is represented by a double aliphatic chain instead of a single one. 
Likely, some steric problems are responsible of this lower interaction. Finally, also the 
Gd2LII-HSA inclusion compound shows no significant change in relaxivity at variable 
temperatures.  
The interaction of Gd4LIV with HSA was also performed, but doesn’t resulted in any 
significant relaxivity enhancement probably because the aliphatic chains are not 
sufficiently available for interaction with the hydrophobic pocket of HSA.   
 
 
5.2.3 Mixed micelles and inclusion into liposome bi-layer  
 
 
Aliphatic chains can be used to include amphiphilic paramagnetic complexes in 
liposomes or combined with phospholipids to give mixed micelles. For all the three 
compounds the mixed micelles were prepared with the following procedure: the dry 
complex was suspended in a 1:1 chloroform / methanol solution and mixed with 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethyleneglycol) 2000 
(DSPE-PEG2000) then slowly evaporated in vacuo, to form the lipidic film, and dried.  
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Then, the film was rehydrated with water and filtered, obtaining the final mixed-
micelles suspension.  
Figure 5.13: left) NMRD profile of the GdLI-DSPE-PEG2000 50:50, 298 K and [Gd] = 
0.776 mM; right) r1p as a function of temperature, measured at 20 MHz. 
 
In Figure 5.13 the NMRD profile of the solution containing the GdLI-DSPE-PEG2000 
50:50 mixed micelles at 298 K and the r1p dependence from temperature are reported. 
The shape of the peak in the profile is quite similar with that one related to the self-
assembled complex, with slightly lower relaxivity (24.2 mM-1 s-1) with respect to the 
micelles 100% made of GdLI  (29.0 mM-1 s -1). The behaviour of relaxivity as a function 
of temperature is another significant difference with the self-assembled micelles, as in 
this case it shows the exponential decay trend typical of systems in the fast water 
exchange regime. The NMRD profile was also fitted with the Lipari-Szabo approach, 
obtaining the best-fit parameters reported in Table 5.2. 
parameter GdLI-DSPE-PEG2000 50:50 
298r1p (mM-1 s-1)[b] 27.7 
Δ2 / 1019 s-2 1.78 
298τV / ps 35.6 
298kex / 106 s-1 12.5 
298τRg (ns) 2.3 
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298τRl (ps) 123 
S2 0.41 
q [a] 2 
r / Å [a] 3.0 
a / Å [a] 4.0 
298D / 10-5 cm2 s-1 [a] 3.1 
 
Table 5.2: Best-fit parameters obtained from the analysis of 1H NMRD profiles of 
GdLI-DSPE-PEG2000 50:50. 
 
 
Figure 5.14: DLS analysis of the GdLI-DSPE-PEG2000 50:50 suspension. 
 
Figure 5.15: left) NMRD profile of the Gd2LII-DSPE-PEG2000 40:60, 298 K and [Gd] 
= 0.306 mM; right) r1p as a function of temperature, measured at 20 MHz. 
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DLS analysis of the mixed micelles suspension was also performed, obtaining particles 
dimension of 12.2 nm (Figure 5.14). 
A mixed micelles suspension was also prepared using Gd2LII, mixed with DSPE-
PEG2000 in a different ratio (40:60).  
 
Also in this case, r1p of Gd2LII-DSPE-PEG2000 40:60 mixed micelles (Figure 5.15) is 
lower than that of the pure complex (20.1 mM-1 s-1 compared to 36.6 mM-1 s-1, at 310 K 
and 20 MHz), and the trend of r1p as a function of temperature is again compatible 
with a fast water exchange regime. 
 
 
Figure 5.16: DLS analysis of the Gd2LII-DSPE-PEG2000 40:60 suspension. 
 
 
In Figure 5.16 the DLS analysis for the Gd2LII-DSPE-PEG2000 40:60 mixed micelles is 
reported, showing particles dimension of 9.24 nm.  
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Finally, micelles including Gd4LIV mixed with DSPE-PEG2000 in 20:80 ratio were 
prepared. In this case the r1p value obtained for the mixed micelles suspension solution 
was 25.8 mM-1 s-1, higher than the value of 20.1 mM-1 s-1 relative to the pure complex 
(Figure 5.17). Once again r1p as a function of temperature shows a fast water regime 
system. 
 
Figure 5.17: left) NMRD profile of the Gd4LIV-DSPE-PEG2000 20:80, 298 K and [Gd] 
= 2.7 mM; right) r1p as a function of temperature, measured at 20 MHz. 
The increase in relaxivity compared with the micelles 100% made by the Gd-complex 
is likely attributable to a more ordered disposition of the amphihilic complex on the 
micelle surface, maybe avoiding some interferences between near paramagnetic 
centres in the coordinated water molecules exchange. The NMRD profile was also 
fitted using the Lipari-Szabo approach and the best-fit parameters obtained this way 
are reported in Table 5.3. 
   
parameter Gd4LIV-DSPE-PEG2000 20:80 
298r1p (mM-1 s-1)[b] 28.1 
Δ2 / 1019 s-2 1.77 
298τV / ps 41 
298kex / 106 s-1 12.5 
298τRg (ns) 2.3 
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298τRl (ps) 196 
S2 0.35 
q [a] 2 
r / Å [a] 3.0 
a / Å [a] 4.0 
298D / 10-5 cm2 s-1 [a] 3.1 
 
Table 5.3: Best-fit parameters obtained from the analysis of 1H NMRD profiles of 
Gd4LIV-DSPE-PEG2000 20:80. 
 
DLS analysis of the Gd4LIV-DSPE-PEG2000 20:80 mixed micelles suspension was also 
performed, defining a particles dimension of 13.3 nm, as showed in Figure 5.18. 
 
Figure 5.18: DLS analysis of the Gd4LIV-DSPE-PEG2000 20:80 suspension. 
 
As last system presented in this work, the preparation of a liposome made of Gd4LIV, 
DSPE-PEG2000 and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) in 20:5:25 
ratio was carried out.  
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After preparation of the lipidic film and drying, the rehydrated film (using HEPES 
buffer) was extruded using first a 400 μm and then a 200 μm membrane, obtaining the 
final liposomal suspension. The NMRD profiles were  measured, obtaining a r1p value 
of 33.2 mM-1 s-1 at 310 K and 20 MHz (Figure 5.19), higher than that of the self-
aggregated and mixed micelles, as showed in Figure 5.20. 
 
Figure 5.19: left) NMRD profile of the Gd4LIV-DSPE-PEG2000-DPPC 20:5:75 
liposomes, 298 K and [Gd] = 1.34 mM; right) r1p as a function of temperature, 
measured at 20 MHz. 
 
r1p as a function of temperature doesn’t highlight any significant modification at 
variation of the temperature. However, in case of liposomes, typically half of the 
amphiphilic complexes point to the internal aqueous core and do not contribute to the 
overall relaxivity in the same amount that the complexes pointing outwards. The basic 
concept is that the Gd-complexes exposed on the external leaflet of the bilayer directly 
affect the nuclear magnetic relaxation rate of the bulk water protons, which are by far 
the predominant fraction of water in the liposomal suspension (>98% under the 
experimental conditions used). The relaxivity contribution of the complexes facing the 
internal aqueous core depends largely by the water permeability of the phospholipidic 
membrane. Being the water permeability directly proportional to the temperature, the 
contribution of the internal complexes should increase with the temperature. This 
could be the reason of the r1p vs temperature trend of Gd4LIV-DSPE-PEG2000-DPPC 
liposomes. 
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Also a DLS analysis of the liposomal suspension was performed, defining a liposomes 
diameter of 100 nm (Figure 5.20). 
 
 
Figure 5.20: DLS analysis of the Gd4LIV-DSPE-PEG2000-DPPC 20:5:75 liposomes 
suspension. 
 
 
5.3 Conclusions 
 
In the literature there are only few examples of aggregated systems based on 
amphiphilic Gd3+ complexes with two coordinated water molecules, being Gd-
AAZTAC17 one of them[ref]. Interestingly, the r1p value for GdLI at 20 MHz and 310 
K  is slightly higher than that reported for GdAAZTAC17 and almost double if 
compared with q = 1 systems.[3,4,5]  High r1p values were obtained also embedding 
Gd4LIV in liposomes, much higher than those observed for systems incorporating q = 
1 complexes such as Gd-DOTAGAC12. The reason of this remarkable increase of 
relaxivity is mainly due to the presence of two coordinated water molecules and to 
their high rate of water exchange. The effects of the use of multimeric systems and of 
the increased local rigidity expected by using the double aliphatic chains 
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functionalization are less pronounced. A further, significant increase of r1p requires a 
more detailed study on the dynamics of these systems and its dependence on the 
details of the molecular structure. 
 
5.4 Experimental part 
 
Synthesis of VII 
A solution of AAZTA-OH (350 mg; 0.582 mmol) in dry CH2Cl2 (5 mL) was added 
under N2 to a solution of p-nitrophenylisocyanate (115 mg; 0.699 mmol) in dry CH2Cl2 
(5 mL). The reaction mixture was stirred for 2 hours at room temperature and then 
evaporated in vacuo. The crude product was purified on silica gel chromatography 
column (petroleum ether/ethyl acetate 8/2) yielding 1 as pale yellow solid (428 mg; 
96%). TLC (silica gel 60 F254, petroleum ether/EtOAc 8 : 2, detection: UV 254 nm): 
Rf=0.45. 1H-NMR (CDCl3) 500 MHz d = 8.53 (bs, 1H, NH), 8.12 (d, 2H, J = 9.2 Hz, CH), 
7.57 (m, 2H, CH), 4.21 (s, 2H, CH2OCO), 3.65 (s, 4H, CH2CO), 3.22 (s, 4H, CH2CO), 3.05 
(d, 2H, J = 14.3 Hz, CH2C), 2.76–2.65 (m, 6H, CH2cycl), 1.40 (s, 18H, CH3), 1.39 (s, 18H, 
CH3). 13C-NMR (CDCl3) 125 MHz d = 172.8, 170.7 (CO), 153.1 (NHCOO), 144.7, 142.7 
(C), 125.2, 117.7 (CH), 81.0, 80.9 (CCH3), 68.0 (CH2OCO), 63.3 (C), 62.0, 60.4 (CH2CO), 
59.1, 51.8 (CH2cycl), 28.2, 28.1 (CH3). ESI-MS+ (m/z): 766.55 [M + H]+; calc for 
C37H60N5O12: 766.42.  
 
Synthesis of VIII 
A suspension of 10% Pd/C (70 mg) in water (1 mL) was added to a solution of VII (115 
mg; 0.15 mmol) in MeOH (10 mL). The mixture, under H2 atmosphere, was stirred for 
3 hours and then filtered over celite. The filtrate was evaporated in vacuo affording 
pure 2 (103 mg; 93%). TLC (silica gel 60 F254, petroleum ether/EtOAc 8 : 2, detection: 
UV 254 nm): Rf=0.13.1H-NMR (CDCl3) 500 MHz d = 7.22 (s, 2H, J = 5.9 Hz, CH), 6.64 
(d, 2H, J = 5.9 Hz, CH), 4.16 (s, 2H, CH2OCO), 3.71 (s, 4H, CH2CO), 3.40 (bs), 2.88 (bs) 
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(12H, CH2CO + CH2cycl), 1.43 (s, 36H, CH3). 13C-NMR (CDCl3) 125 MHz d = 172.7, 170.6 
(bs) (CO), 153.6 (NHCOO), 140.0, 130.1 (C), 120.5, 115.7 (CH), 81.2 (bs) (CCH3), 67.4 
(bs) (CH2OCO), 61.7 (bs), 58.8 (bs), 51.8 (bs) (C, CH2CO, CH2cycl), 28.2 (CH3). ESI-MS+ 
(m/z): 736.25 [M + H]+; calc for C37H62N5O10: 736.45. 
 
Synthesis of IX 
A solution of thiosphogene (17 μL; 0.23 mmol) in dry CH2Cl2 (2 mL) was added drop 
wise in 2 minutes to an ice-bath cooled mixture of VIII (110 mg; 0.15 mmol) in 
saturated potassium bicarbonate (5 mL) and CH2Cl2 (5 mL), under vigorous magnetic 
stirring. The ice-bath was removed after 5 minutes and the suspension was stirred for 
2 hours at room temperature. The organic phase was separated and extracted with 
water (3 x 10 mL); then the organic phase was dried over Na2SO4, filtered and 
evaporated to yield a yellow solid. TLC (silica gel 60 F254, petroleum ether/EtOAc 8 : 
2, detection: UV 254 nm): Rf=0.41. 1H-NMR (CDCl3) 500 MHz d = 7.41 (bs, 2H, CH), 
7.20 (bs, 2H, CH), 7.15 (bs, 1H, NH), 4.20 (s, 2H, CH2OCO), 3.72 (s, 4H, CH2CO), 3.21 
(s, 4H, CH2CO), 3.12 (d, 2H, J = 14.3 Hz, CH2C), 2.87 (d, 2H, J = 14.3 Hz, CH2C), 2.70–
2.64 (m, 4H, CH2CH2), 1.44 (s, 18H, CH3), 1.43 (s, 18H, CH3). 13C-NMR (CDCl3) 125 
MHz d = 172.9, 170.4 (CO), 153.3 (NHCOO), 140.0 (C), 128.0 (C), 110.3 (CH), 106.7 (CH), 
81.4, 81.2 (CCH3), 67.6 (CH2OCO), 63.4 (C), 62.2, 62.3 (CH2CO), 59.0, 51.6 (CH2cycl), 28.2, 
28.0 (CH3). ESI-MS+ (m/z): 778.47 [M + H]+; calc for C38H60N5O10S: 778.41.  
 
Synthesis of X 
A solution of IX (45 mg; 0.058 mmol) in dry CH2Cl2 (3 mL) was added under N2 to a 
solution of dodecylamine (53 μL; 0.231 mmol) in dry CH2Cl2 (2 mL). The reaction 
mixture was stirred for overnight at room temperature and then evaporated in vacuo. 
The crude product was purified on silica gel chromatography column (petroleum 
ether/ethyl acetate 7/3) yielding 1 as pale yellow solid (50 mg; 90%). TLC (silica gel 
60 F254, petroleum ether/EtOAc 7 : 3, detection: UV 254 nm): Rf=0.20. 1H-NMR 
(CDCl3) 500 MHz d = 7.41 (bs, 2H, CH), 7.20 (bs, 2H, CH), 7.15 (bs, 1H, NH), 4.20 (s, 
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2H, CH2OCO), 3.72 (s, 4H, CH2CO), 3.21 (s, 4H, CH2CO), 3.12 (d, 2H, J = 14.3 Hz, 
CH2C), 2.87 (d, 2H, J = 14.3 Hz, CH2C), 2.70–2.64 (m, 4H, CH2CH2), 1.44 (s, 18H, CH3), 
1.43 (s, 18H, CH3). 13C-NMR (CDCl3) 125 MHz d = 172.9, 170.4 (CO), 153.3 (NHCOO), 
140.0 (C), 128.0 (C), 110.3 (CH), 106.7 (CH), 81.4, 81.2 (CCH3), 67.6 (CH2OCO), 63.4 (C), 
62.2, 62.3 (CH2CO), 59.0, 51.6 (CH2cycl), 28.2, 28.0 (CH3). ESI-MS+ (m/z): 965.62 [M + 
H]+; calc for C38H60N5O10S: 965.91. 
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